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Summary  The  Eleventh  Eilat  Conference  on  New  Antiepileptic  Drugs  (AEDs)-EILAT  XI,  took
place  in  Eilat,  Israel  from  the  6th  to  10th  of  May  2012.  About  100  basic  scientists,  clinical  phar-
macologists  and  neurologists  from  20  countries  attended  the  conference,  whose  main  themes
included  ‘‘Indications  overlapping  with  epilepsy’’  and  ‘‘Securing  the  successful  development
of  an  investigational  antiepileptic  drug  in  the  current  environment’’.  Consistent  with  previ-
ous  formats  of  this  conference,  a  large  part  of  the  program  was  devoted  to  a  review  of  AEDs
in  development,  as  well  as  updates  on  AEDs  introduced  since  1994.  Like  the  EILAT  X  report,
the  current  manuscript  focuses  only  on  the  preclinical  and  clinical  pharmacology  of  AEDs  that
are  currently  in  development.  These  include  brivaracetam,  2-deoxy-glucose,  ganaxolone,  ICA-
105665,  imepitoin,  NAX  801-2,  perampanel  and  other  AMPA  receptor  antagonists,  tonabersat,
valnoctamide  and  its  homologue  sec-propylbutylacetamide  (SPD),  VX-765  and  YK3089.  Since  the
previous  Eilat  conference,  retigabine  (ezogabine)  has  been  marketed  and  four  newer  AEDs  in
development  (NAX  810-2,  SPD,  tonabersat  and  VX-765)  are  included  in  this  manuscript.
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Pharmacology
The  preclinical  activity  proﬁle  of  brivaracetam  in  a  wide
range  of  animal  models  of  focal  and  generalized  seizuresReferences ................................................
rivaracetam (ucb34714)
arah  Lua,  Armel  Stockisb,  Alain  Matagneb,  Martin  Johnsona
aUCB  Pharma,  Raleigh,  NC,  USA
bUCB  Pharma,  Braine-l’Alleud,  Belgiumntroduction  and  rationale  for  development
rivaracetam  (UCB  34714)  is  a  novel  high-afﬁnity  synap-
ic  vesicle  protein  2A  (SV2A)  ligand  (Kenda  et  al.,  2004;
ynch  et  al.,  2004). Brivaracetam  also  displays  inhibitory
ctivity  at  neuronal  voltage-dependent  sodium  channels
Niespodziany  et  al.,  2009;  Zona  et  al.,  2010). Brivaracetam
s  currently  in  Phase  III  development  for  epilepsy.
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Table  1  Anticonvulsant  proﬁle  of  investigational  AEDs  in  mouse  models.
Compound Route Time of
test (min)
ED50 TD50 (mg/kg) In vivo activity in other model
systems
MES s.c. PTZ 6 Hz, 22 mA 6 HZ, 32 mA 6 Hz, 44 mA Audiogenic
seizures
Brivaracetam (UCB
34174)
i.p. 30 113 30 NT4 NT 4.4 2.4 55 (kindled mice) Active in corneal kindled mouse
(ED50: 1.2 mg/kg), and on
development of corneal kindling;
active in phenytoin-resistant
amygdala-kindled rat
2-Deoxy-D-glucose i.p. 15—120 NT NT 79.7 NT NT 206 NA
Ganaxolone i.p. 30 29.7 3.5 NT 6.3 NT NT 33.4 Active against bicuculline- and
aminophylline-induced seizures
(ED50’s: 4.6 and 11.5 mg/kg,
respectively)
ICA-105665 i.p. 30 8.1 13 NT 9.8 9.4 0.91 34 Elevates i.v. PTZ seizure
threshold
Imepitoin (AWD
131—138 or ELB
138)
i.p. 30 94. 17 NT NT NT 2.6 (DBA);
5.0 (Frings)
176 Active in mouse and rat models
of anxiety including innate fear
and fear induced by open and
high areas and light stimulation
(e.g., elevated maze, light-dark
chamber, social interaction test)
at doses as low as 3 mg/kg, i.p.
and p.o.
NAX 810-2 i.p. 60 >20 NT NT 2.5 5.9 9.2 >32 Active in corneal kindled mouse
(ED50: 7.4 mg/kg); active in
mouse formalin and carrageenan
models of inﬂammatory pain
Perampanel (E2007) i.p. 60 1.6 NT NT NT NT 0.47 NT
p.o. 60 NT 0.94 NT 2.1 2.8 NT 1.8
SPD i.p. 15 71 62 NT 27 NT 20 (Frings) 88 Blocks minimal clonic seizures
induced by s.c. picrotoxin and
bicuculline and secondarily
generalized seizures in the
corneal kindled mouse with
ED50’s of 17, 94, and 39 mg/kg,
respectively.
Tonabersat i.p. 15—240 4.7 >250 NT >5.0 NT 0.12 >250 Inhibits tonic but not myoclonic
seizures induced by PTZ
VCD (rac) i.p. 15 58 32 37 67 77
(2S,3S)-VCD i.p. 15 132 69 25 33 80 128
(2R,3S)-VCD i.p. 15 119 67 19 48 67 127
YKP 3089 i.p. 15 9.8 28.5 11 17.9 16.5 NT 58 Anxiety; HI-induced lethality;
s.c. picrotoxin-induced clonus
ED50, median effective dose in mg/kg; TD50, median toxic dose in mg/kg;HI, Hypoxia Ischemia; i.p., intraperitoneal; i.v., intravenous; p.o., per os; MED, median effective dose; NT, not
tested; MES, maximal electroshock seizure; sc, subcutaneous; PTZ, pentylenetetrazol; SPD, sec-Butyl-propylacetamide; VCD, valnoctamide.
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nd  epilepsy  (Table  1)  (Matagne  et  al.,  2008) suggests  poten-
ial  broad  spectrum  activity  with  a  potency  and  efﬁcacy
uperior  to  levetiracetam.  Data  suggest  that  brivaracetam
as  anticonvulsant  and  disease-modifying  effects  against
efractory  self-sustaining  status  epilepticus  in  rats,  and
hat  brivaracetam  is  effective  at  lower  doses  when  com-
ined  with  low-dose  diazepam  (Wasterlain  et  al.,  2009).
he  preclinical  proﬁle  of  brivaracetam  has  been  summarized
reviously  (Bialer  et  al.,  2010).
Doses  of  brivaracetam  that  exert  anticonvulsant  effects
n  amygdala-kindled  rats  were  devoid  of  negative  impact  on
earning  and  memory  performance  in  normal  and  amygdala-
indled  rats  evaluated  in  the  Morris  water  maze  (Detrait
t  al.,  2010). Furthermore,  brivaracetam  did  not  affect
ong-term  potentiation  in  hippocampal  slices.  These  ﬁnd-
ngs  suggest  that  brivaracetam  would  not  be  expected  to
ave  detrimental  effects  on  hippocampal-dependent  cogni-
ive  function  in  patients  with  epilepsy.
A  strong  functional  correlation  between  in  vitro  SV2A
inding  afﬁnity  and  anticonvulsant  potency  in  animal  models
f  both  focal  and  generalized  epilepsy  has  been  estab-
ished  (Kaminski  et  al.,  2008). Consistent  with  these  ﬁndings,
x  vivo  binding  studies  demonstrated  that  the  time-  and
ose-dependency  of  brivaracetam  binding  to  brain  SV2A
as  correlated  with  seizure  protection  in  audiogenic  mice
Gillard  et  al.,  2011). Brivaracetam  was  more  potent  and
aster  than  levetiracetam  in  achieving  maximal  SV2A  occu-
ancy  and  seizure  protection.
Simulations  based  on  in  vitro  and  ex  vivo  binding  exper-
ments  in  mice  predicted  that,  at  50  mg/day,  brivaracetam
hould  occupy  more  than  80%  of  SV2A  in  patients  with
pilepsy  (Gillard  et  al.,  2011). Similarly,  human  brain  con-
entrations  of  brivaracetam  predicted  using  physiological
odels,  combined  with  mouse  ex  vivo  binding  phar-
acokinetic/pharmacodynamic  modeling,  estimated  that
rivaracetam  50  mg/day  would  occupy  approximately  50%
f  SV2A  in  human  brain  (Brochot  et  al.,  2010).
oxicology
rivaracetam  demonstrated  low  acute  oral  toxicity  in  mice,
ats,  and  dogs.  Toxicology  data  have  been  summarized  pre-
iously  (Bialer  et  al.,  2009).
linical  pharmacokinetics
rivaracetam  is  well  absorbed  from  the  gastrointestinal
ract  and  shows  linear  pharmacokinetics  following  single
ral  doses  up  to  600  mg  (Sargentini-Maier  et  al.,  2007;  von
osenstiel  and  Perucca,  2009). The  extent  of  binding  to
lasma  proteins  is  small  (≤20%)  (Sargentini-Maier  et  al.,
008a)  and  the  volume  of  distribution  is  in  the  order  of
.6  L/kg  (Rolan  et  al.,  2008). The  half-life  of  brivaracetam  is
bout  8  h  (Rolan  et  al.,  2008;  Sargentini-Maier  et  al.,  2007).
Brivaracetam  is  eliminated  primarily  by  biotransfor-
ation  through  hydrolysis  of  the  acetamide  group  and
YP2C19-mediated  hydroxylation  (Sargentini-Maier  et  al.,
008a;  von  Rosenstiel  and  Perucca,  2009). The  metabolites
re  pharmacologically  inactive  and  do  not  accumulate  in
lasma  to  any  signiﬁcant  extent  (von  Rosenstiel  and  Perucca,
009;  Sargentini-Maier  et  al.,  2008a).  After  administration
(
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f  a  radiolabelled  dose  of  brivaracetam,  over  95%  of  the
adioactivity  is  recovered  in  urine  within  72  h,  of  which  less
han  10%  is  represented  by  unchanged  drug  (Rolan  et  al.,
008;  Sargentini-Maier  et  al.,  2008a). The  CYP2C19  genetic
olymorphism  has  only  a  modest  inﬂuence  on  brivarac-
tam  pharmacokinetics,  with  a  30%  decrease  in  clearance
f  brivaracetam  being  reported  in  subjects  with  inactive  *2
r  *3  mutations  (Stockis  et  al.,  2011). As  a  result,  no  dose
djustments  are  considered  necessary  in  subjects  bearing
YP2C19  mutations  (Bialer  et  al.,  2010).
In  population  pharmacokinetic  studies  using  data  from
atients  included  in  Phase  II  and  III  trials,  plasma  brivarac-
tam  levels  were  not  found  to  be  signiﬁcantly  affected  by
ender,  age,  race,  dose,  renal  function  (creatinine  clear-
nce),  and  concomitant  AEDs,  except  for  enzyme  inducing
EDs  which  were  associated  with  increased  brivaracetam
learance  (Bialer  et  al.,  2010). The  pharmacokinetic  pro-
le  of  brivaracetam  in  the  elderly  (Sargentini-Maier  et  al.,
008b) and  in  subjects  with  severe  renal  impairment  not
equiring  dialysis  (creatinine  clearance  <  15  mL/min,  n  =  6;
5—29  mL/min,  n  =  3)  (Sargentini-Maier  et  al.,  2012) did  not
iffer  to  a  major  extent  from  those  found  in  non-elderly
ealthy  subjects.  In  subjects  with  severe  hepatic  impair-
ent  (Child-Pugh  Class  C),  exposure  to  brivaracetam  is
ncreased  by  up  to  50—60%  compared  with  healtly  control
ubjects  (Stockis  et  al.,  2008).
rug  interactions
n  adjunctive-therapy  trials  in  patients  with  epilepsy,
rivaracetam  treatment  was  found  not  to  cause  sig-
iﬁcant  changes  in  the  plasma  concentrations  of  car-
amazepine,  lamotrigine,  levetiracetam,  monohydroxy-
arbazepine  (licarbazepine),  phenobarbital,  phenytoin,
opiramate,  valproic  acid,  or  zonisamide.  The  concentra-
ions  of  the  10,11-epoxide  metabolite  of  carbamazepine
ere  increased  at  brivaracetam  doses  of  ≥50  mg/day,  and
t  doses  of  100—150  mg/day  it  approached  a  concentra-
ion  of  3.0  g/mL,  which  is  close  to  the  upper  limit  of  the
ange  found  in  subjects  not  receiving  brivaracetam.  These
ata  suggest  that  monitoring  for  potential  carbamazepine-
ssociated  adverse  effects  is  indicated  when  brivaracetam
s  added  on  to  the  therapeutic  regimen  of  patients  stabilized
n  high  doses  of  carbamazepine  (Bialer  et  al.,  2010).
At  a  dose  of  100  mg/day,  brivaracetam  did  not  mod-
fy  the  pharmacokinetics  of  the  components  of  an  oral
ontraceptive  steroid  (30  g  ethinylestradiol  and  150  g  lev-
norgestrel)  (Stockis  et  al.,  2009). In  the  same  study,  the
ral  contraceptive  did  not  affect  trough  brivaracetam  con-
entrations.
fﬁcacy  data
hase  IIb  studies
wo  randomized,  double-blind,  placebo-controlled
djunctive-therapy  Phase  IIB  studies  were  completed
n  patients  (16—65  years  old)  with  partial-onset  seizures
POS)  uncontrolled  despite  treatment  with  up  to  2  con-
omitant  AEDs.  In  study  N01193  (NCT00175825),  which
ssessed  brivaracetam  doses  of  5,  20,  and  50  mg/day,  the
ercent  reduction  over  placebo  in  baseline-adjusted  POS
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frequency  (primary  efﬁcacy  endpoint)  achieved  statistical
signiﬁcance  for  the  50  mg/day  dose  (p  =  0.004)  (French
et  al.,  2010). Secondary  efﬁcacy  analysis  (≥50%  respon-
der  rate  and  median  percent  reduction  from  baseline  in
POS  frequency/week)  provided  supportive  evidence  for
the  efﬁcacy  of  brivaracetam  20  mg/day.  In  Study  N01114
(NCT00175929),  which  assessed  brivaracetam  doses  of
50  and  150  mg/day,  no  statistically  signiﬁcant  difference
between  brivaracetam  and  placebo  was  found  for  the
primary  efﬁcacy  endpoint  (Van  Paesschen  et  al.,  2007).
However,  a  clear  differentiation  from  placebo  was  found  on
several  secondary  efﬁcacy  endpoints  for  both  brivaracetam
doses.
Phase  III  ﬁxed-dose  studies
Two  randomized,  double-blind,  placebo-controlled
adjunctive-therapy  Phase  III  trials  were  conducted  in
adults  (16—70  years  old)  with  refractory  POS  receiving  up
to  2  concomitant  AEDs.  In  both  trials,  brivaracetam  was
administered  b.i.d.  for  12  weeks  without  titration  and
the  primary  efﬁcacy  endpoint  was  percent  reduction  over
placebo  in  baseline-adjusted  POS  frequency.  Statistical
comparisons  were  conducted  in  a  pre-deﬁned  order  starting
with  50  mg/day  for  both  studies.
In  study  N01253  [NCT00464269],  which  assessed  doses  of
5,  20  and  50  mg/day  in  a  total  of  400  randomized  patients,
statistical  signiﬁcance  versus  placebo  (p  =  0.02)  was  reached
for  the  primary  efﬁcacy  endpoint  for  the  50  mg/day  dose,
but  not  for  the  lower  doses  (Biton  et  al.,  2009). In  study
N01252  [NCT00490035],  which  investigated  doses  of  20,
50  and  100  mg/day  in  399  patients,  statistical  signiﬁcance
versus  placebo  on  the  primary  efﬁcacy  endpoint  (p  =  0.261)
was  not  achieved  for  the  predeﬁned  initial  comparison  at
50  mg/day  (Biton  et  al.,  2009). Statistical  signiﬁcance,  how-
ever,  was  achieved  for  100  mg/day  at  the  nominal  0.05
signiﬁcance  level,  a  ﬁnding  which  was  supported  by  the  sec-
ondary  efﬁcacy  analyses  (≥50%  responder  rate  and  median
percent  POS  frequency  reduction)  at  the  100  mg/day  dose
(Bialer  et  al.,  2010).
Phase  III  ﬂexible-dose  study
A  prospective,  multicenter,  randomized,  double-blind,
placebo-controlled,  parallel-group,  ﬂexible-dose  trial
(N01254  [NCT00504881])  was  conducted  in  adults  (16—70
years)  with  uncontrolled  POS  or  generalized  seizures  despite
treatment  with  1—3  concomitant  AEDs  (Kwan  et  al.,  2010).
Brivaracetam  was  initiated  at  20  mg/day  and  increased
stepwise  to  a  maximum  of  150  mg/day  at  the  investiga-
tor’s  discretion.  Four  hundred  and  eighty  patients  were
randomized  (359  brivaracetam,  121  placebo);  431  (89.8%)
with  POS  and  49  (10.2%)  with  primary  generalized  seizures.
During  the  16-week  treatment  period,  median  percent
reduction  from  baseline  in  POS  frequency/week  was  26.9%
for  brivaracetam  versus  18.9%  for  placebo  (p  =  0.070);
50%  responder  rates  were  30.3%  for  brivaracetam  versus
16.7%  for  placebo  (p  =  0.006).  Preliminary  data  suggest
potential  efﬁcacy  of  adjunctive  brivaracetam  in  adults  with
generalized  epilepsy.  Of  the  49  patients  with  primary  gen-
eralized  seizures,  34/36  (94.4%)  who  received  brivaracetam
and  13/13  (100%)  who  received  placebo  completed  the  16-
week  treatment  period  (Kwan  et  al.,  2010). Seizure  types
t
(
u7
xperienced  during  the  baseline  period  were  tonic-clonic
21  brivaracetam,  8  placebo),  absence  (12  brivaracetam,
 placebo),  tonic  (6  brivaracetam,  1  placebo),  myoclonic
5  brivaracetam,  0  placebo),  clonic  (1  brivaracetam,  2
lacebo)  and  atonic  (1  brivaracetam,  1  placebo).  Median
aseline  generalized  seizure  days/week  was  similar  in  both
roups  (brivaracetam  1.42;  placebo  1.47).  Exploratory
fﬁcacy  analysis  showed  that  during  the  treatment  period
he  median  generalized  seizure  days/week  decreased
o  0.63  on  brivaracetam  and  remained  relatively  stable
n  placebo  (1.26).  Median  percentage  reductions  from
aseline  and  ≥50%  responder  rates  in  generalized  seizure
ays/week  were  higher  on  brivaracetam  (42.6%  and  44.4%,
espectively)  compared  with  placebo  (20.7%  and  15.4%,
espectively).  Three  (8.3%)  patients  on  brivaracetam  were
eizure-free  during  the  entire  treatment  period  compared
ith  none  on  placebo.
olerability  and  adverse  event  proﬁle
n  all  studies  conducted  to  date,  brivaracetam
5—150  mg/day)  showed  a  favourable  safety  and  toler-
bility  proﬁle  (Brodsky  et  al.,  2007;  Biton  et  al.,  2009).
n  the  two  Phase  III  ﬁxed-dose  studies,  a  similar  propor-
ion  of  patients  on  brivaracetam  (range:  56.6—79.0%)
eported  at  least  one  treatment-emergent  adverse  event
TEAE)  compared  with  placebo  (range:  53.0—70.4%).  In  all
reatment  arms,  the  proportion  of  completers  was  high
range:  84.5—94.0%  for  brivaracetam  versus  92.0—94.9%  for
lacebo)  and  few  patients  discontinued  treatment  due  to
EAEs  (range:  4.0—8.2%,  for  brivaracetam  versus  2.0—4.0%
or  placebo).  These  favourable  safety  and  tolerability
esults  were  conﬁrmed  by  the  Phase  III  ﬂexible-dose  trial,
n  which  a  similar  proportion  of  brivaracetam  and  placebo
atients  reported  at  least  one  TEAE  (66.0%  vs  65.3%)  (UCB,
ata  on  ﬁle).  Completion  rates  were  90%  for  brivaracetam
nd  91.7%  for  placebo,  and  discontinuation  rates  for  TEAEs
ere  6.4%  for  brivaracetam  and  5.8%  for  placebo  (Kwan
t  al.,  2009). The  majority  of  TEAEs  reported  in  the  Phase
II  trials  were  mild  to  moderate.  Those  reported  most
requently  were  headache  (range:  brivaracetam  6.0—18.2%,
lacebo  9.0—19.8%),  somnolence  (range:  brivaracetam
.1—16.8%,  placebo  4.1—7.1%),  dizziness  (range:  brivarac-
tam  5.0—15.8%,  placebo  5.0—9.2%),  and  fatigue  (range:
rivaracetam  3.0—13.0%,  placebo  2.0—4.1%)  (Biton  et  al.,
009;  Kwan  et  al.,  2009).
In a  well  controlled  QT  safety  study  in  healthy  subjects,
rivaracetam  (75  and  400  mg  b.i.d.)  was  found  not  to  affect
ardiac  repolarization  (Rosillon  et  al.,  2008).
ngoing  clinical  studies
 Phase  III,  randomized,  double-blind,  placebo-controlled,
xed-dose  study  (N01358,  NCT01261325)  in  adults  with
OS  inadequately  controlled  with  1—2  concomitant  AEDs
as  been  initiated  to  evaluate  the  efﬁcacy  and  safety
f  brivaracetam  100  and  200  mg/day  as  adjunctive
reatment.
Three  Phase  III,  open-label,  multicenter,  ﬂexible-dose
up  to  a  maximum  dose  of  150  mg/day)  long-term  follow-
p  trials  (N01125,  NCT00175916;  N01199,  NCT00150800;
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01315,  NCT00761774)  are  ongoing  to  evaluate  the  long-
erm  safety/tolerability  and  maintenance  of  efﬁcacy  of
rivaracetam  in  patients  with  epilepsy  who  had  participated
n  previous  trials.
A  multicenter,  open-label,  adjunctive-therapy  random-
zed  trial  (N01258,  NCT01405508)  is  ongoing  to  investigate
he  safety  and  tolerability  of  brivaracetam  200  mg/day
dministered  intravenously  as  an  infusion  or  bolus  in  adults
ith  POS  or  generalized  seizures.
A multicenter,  open-label  trial  (N01263,  NCT00422422)
s  ongoing  to  evaluate  the  steady  state  pharmacokinetics,
afety,  and  preliminary  efﬁcacy  of  adjunctive  brivaracetam
n  children  with  any  type  of  epilepsy  aged  from  at  least  1
onth  to  16  years.  The  dose  of  brivaracetam  is  adjusted  by
ody  weight  to  achieve  similar  exposure  to  adults  at  doses
f  50—200  mg/day.
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ntroduction
-Deoxy-D-glucose  is  a  glucose  analogue  and  glycolytic
nhibitor.  The  anticonvulsant  and  disease-modifying
ntiepileptic  properties  of  2-deoxy-D-glucose  were  deﬁned
n  animal  models  during  investigations  aimed  at  eluci-
ating  the  mechanisms  underlying  the  efﬁcacy  of  the
etogenic  diet.  2-Deoxy-D-glucose  is  currently  in  preclinical
evelopment  for  the  treatment  of  epilepsy.  More  detailed
nformation  on  this  compound  can  be  found  in  the  reports
f  previous  Eilat  conferences  (Bialer  et  al.,  2009  and
010).
harmacologylycolytic  inhibition  by  2-deoxy-D-glucose
-Deoxy-D-glucose  undergoes  activity-dependent  uptake
nto  cells  through  glucose  transporters.  It  then  undergoes
hosphorylation  to  2-deoxy-D-glucose-6-phosphate,  which
m
c
(
wM.  Bialer  et  al.
annot  undergo  isomerization  to  fructose-6-phosphate,
hereby  preventing  subsequent  steps  of  glycolysis.
nticonvulsant  proﬁle  in  experimental  models
-Deoxy-D-glucose  displays  both  acute  and  chronic  mecha-
isms  of  action  in  experimental  in  vivo  models.  In  the  mouse
n  vivo  6  Hz  model,  2-deoxy-D-glucose  acutely  protected
gainst  seizures  evoked  by  6  Hz  22  mA  corneal  stimulation
t  doses  of  75—300  mg/kg  i.p.  with  an  ED50 of  79.7  mg/kg
Table  1).  The  time  to  peak  action  was  15  min  at  a  dose  of
5  mg/kg  i.p.  and  1  h  at  a dose  of  100  mg/kg  i.p.  2-Deoxy-
-glucose  protected  against  audiogenic  seizures  evoked  in
rings  mice  2  h after  administration  of  220—250  mg/kg  i.p.
he  ED50 was  206.4  mg/kg,  and  the  time  to  peak  effect  was
 h  at  these  doses.  2-Deoxy-D-glucose  also  demonstrated
vidence  of  anticonvulsant  activity  against  seizures  evoked
y  pentylentetrazol  at  30  min  after  administration  at  doses
f  200—400  mg/kg  i.p.  and  50—400  mg/kg  per  os  (p.o.),  but
verall  the  results  were  not  sufﬁcient  to  calculate  an  ED50
r  a  time  to  peak  effect.  There  was  no  protective  effect  of
-Deoxy-D-glucose  against  MES  in  rats  when  tested  15  min  to
 h  after  administration  of  100—200  mg/kg  p.o.  (Stafstrom
t  al.,  2009).
2-Deoxy-D-glucose  displays  in  vivo  chronic  ‘‘disease-
odifying’’  antiepileptic  effects  consisting  of  2-fold  slowing
f  progression  of  repeated  seizures  evoked  by  perforant
ath  or  olfactory  bulb  kindling  (Garriga-Canut  et  al.,  2006;
tafstrom  et  al.,  2009). These  effects  have  been  observed
t  doses  of  37.5—50  mg/kg  administered  30  min  prior  to
erforant  path  stimulation.  In  addition,  effects  on  disease
rogression  have  been  observed  when  2-Deoxy-D-glucose
as  administered  immediately  after,  and  approximately
0  min  after,  evoked  seizures  (Sutula  and  Franzoso,  2008).
his  novel  ‘‘post-seizure’’  action  is  most  likely  based  on
nhanced  activity-dependent  uptake  of  2-Deoxy-D-glucose
nto  those  brain  regions  with  increased  energy  demand;  e.g.,
yperactive  neural  circuits  as  occurs  during  seizures.  This
ovel  action  of  2-Deoxy-D-glucose  represents  a  potential
pportunity  for  ‘‘post-seizure’’  anticonvulsant  administra-
ion  for  the  treatment  of  seizure  clusters  and  status  epilep-
icus.  2-Deoxy-D-glucose  also  reduces  the  latency  to  seizures
voked  by  pilocarpine  and  kainic  acid  (Lian  et  al.,  2007).
europrotective  action  in  experimental  traumatic  brain
njury  (TBI)
-Deoxy-D-glucose  displays  neuroprotective  effects  against
he  progressive  structural  damage  in  the  frontal  cortex  or
orsal  hippocampus  after  TBI  induced  by  controlled  cortical
mpact  (CCI)  model  using  Sprague  Dawley  rats.  2-Deoxy-
-glucose  also  displays  neuroprotective  effects  following
BI  in  unique  strains  of  rats  bred  for  their  susceptibility
r  resistance  to  kindling  progression  evoked  by  perforant
ath  stimulation  of  the  hippocampus  (Hutchinson  et  al.,
010).  After  CCI,  serial  in  vivo  magnetic  resonance  imag-
ng  (MRI)  and  diffusion  tensor  imaging  (DTI)  performed
ver  a  6  month  period  demonstrate  progresively  increasing
entricle  volume,  increasing  hippocampal  diffusion  abnor-
alities,  and  evolving  patterns  of  hippocampal  and  corpus
allosum  anisotropy.  Brief  treatment  with  2-Deoxy-D-glucose
40  mg/kg  at  the  time  of  injury  and  250  mg/kg/day  for  2
eeks)  did  not  modify  the  severity  of  the  initial  injury.
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However,  this  treatment  with  2-Deoxy-D-glucose  did  reduce
the  progression  of  the  observed  structural  damage  that
was  assessed  by  MRI  and  DTI  measures  over  the  6  month
post-TBI  observation  period.  Distinct  patterns  of  structural
abnormalities  were  observed  in  kindling-susceptible  and
kindling-resistant  rat  strains.  Studies  are  underway  to  eval-
uate  the  possibility  that  treatment  with  2-Deoxy-D-glucose
might  also  have  favorable  effects  on  long-term  conse-
quences  such  as  post-traumatic  epilepsy  and  post-traumatic
stress  disorder.
Toxicology
Cardiac  toxicity  and  increased  incidence  of  pheochro-
mocytomas  were  reported  with  chronic  administration
of  2-deoxy-D-glucose  at  doses  of  0.25—0.4%  of  dietary
intake  (corresponding  to  total  daily  exposures  of
∼125—200  mg/kg/day).  Reduced  life-span  was  also  reported
at  a  daily  dietary  intake  of  0.4%  (Minor  et  al.,  2010). Car-
diotoxicity  was  accompanied  by  myoﬁbrillar  vesicular
alterations  consistent  with  autophagy,  and  subtle  evidence
of  myoﬁbrillar  vesicular  alterations  was  also  reported  at
dietary  exposures  of  about  20—25  mg/kg/day.  As  discussed
in  more  detail  in  a  previous  report  (Bialer  et  al.,  2010),
the  reversibility  and  signiﬁcance  of  these  observations  are
currently  under  investigation.
Experiments  in  rodents  using  the  Morris  water  maze  test
found  no  effects  on  spatial  memory  at  doses  nearly  30  times
greater  than  the  minimum  dose  required  to  reduce  kindling
progression  (Bialer  et  al.,  2010). Further,  no  effects  on  spa-
tial  memory  at  15  min  after  treatment  with  50  or  250  mg/kg,
i.p.  were  observed.  Dose-dependent  effects  in  the  open  ﬁeld
tests  were  reported  at  doses  of  250  mg/kg  i.p.,  but  not  at
doses  of  50  mg/kg  i.p.  (Stafstrom  et  al.,  2007;  Ockuly  et  al.,
2012).
Pharmacokinetics  and  cerebral  uptake  mechanisms
Intravenous  2-Deoxy-D-glucose  (40  mg/kg)  in  normal  human
volunteers  induces  regional  increases  in  cerebral  blood  ﬂow
in  cingulate  gyrus,  sensorimotor  cortex,  superior  tempo-
ral  cortex,  occipital  cortex,  basal  ganglia,  limbic  system,
and  hypothalamus  (Elman  et  al.,  1999), which  are  likely  to
explain  the  shorter  latencies  of  onset  of  behavioral  seizures
in  response  to  intravenous  administration  of  convulsants
reported  in  some  rodent  studies  (Gasior  et  al.,  2010). In
Phase  I  studies  in  human  cancer  patients,  the  half-life  of  of
2-Deoxy-D-glucose  during  14  days  of  once  daily  oral  dosing
at  45  mg/kg  was  7.3—8.2  h  (Stein  et  al.,  2010).
Tolerability  and  safety  in  clinical  studies
2-Deoxy-D-glucose  has  been  evaluated  in  Phase  I/II  cancer
trials  and  reported  to  be  well  tolerated  in  dose  escalation
studies  up  to  64  mg/kg/day  for  5  to  8  weeks  (Raez  et  al.,
2007,  Singh  et  al.,  2005). In  a  recent  open  label  multiple
dose  Phase  I  study  in  patients  with  prostate  cancer,  dose-
limiting  reversible  toxicity  of  grade  3  asymptomatic  QTc
prolongation  was  seen  in  two  patients  treated  at  a  dose  of
b
t
m
a9
0  mg/kg,  but  no  evidence  of  QTc  prolongation  was  observed
t  doses  of  45  mg/kg  (Stein  et  al.,  2010).
lanned  studies
urther  preclinical  toxicology  and  pharmacokinetic  studies
re  planned.  Planned  clinical  studies  include,  in  addition
o  conventional  trial  designs  in  a  variety  of  seizure  types,
rotocols  for  administration  during  seizure  clusters  as  well
s  status  epilepticus  (Bialer  et  al.,  2010).
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ntroduction
anaxolone  (3-hydroxy-3-methyl-5-pregnan-20-one)  is
he  3-methyl  analog  of  the  neurosteroid  allopregnanolone,
 metabolite  of  progesterone.  Like  other  related  neuros-
eroids,  ganaxolone  is  not  believed  to  have  nuclear  hormone
ctivity  and  cannot  be  biotransformed  to  metabolites  with
uch  activity.  Two  Phase  II  clinical  trials  have  shown  that
anaxolone  treatment  signiﬁcantly  reduces  mean  weekly
eizure  frequency  (WSF)  in  adults  with  POS  when  compared
o  placebo,  with  good  tolerability  and  safety  at  doses  of
500—1625  mg/day.  New  data  from  a  104-week  open-label
xtension  of  a  10-week  double-blind  randomized  study  in
dults  with  POS  show  efﬁcacy  is  sustained  long-term  while
aintaining  the  tolerability  proﬁle  seen  in  earlier  studies.
o  new  safety  concerns  were  identiﬁed  during  extended
reatment.
harmacology
eurosteroids  including  ganaxolone  have  two  separate
ffects  on  GABAA receptors:  at  low  concentrations  they
otentiate  the  action  of  GABA  and  at  higher  concentrations
irectly  activate  the  receptor;  these  actions  occur  at  two
istinct  sites  on  the  receptor  complex  that  do  not  corre-
pond  with  the  modulatory  sites  of  benzodiazepines  and
arbiturates  (Hosie  et  al.,  2006). Unlike  benzodiazepines
hat  are  speciﬁc  for  synaptic  GABAA receptors,  neurosteroids
odulate  both  synaptic  and  extrasynaptic  GABAA receptors
nd  their  modulatory  action  is  of  greater  magnitude  for
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xtrasynaptic  GABAA receptor  isoforms  that  contain  a    sub-
nit  (Herd  et  al.,  2007). These  isoforms  have  decreased
xpression  in  rodent  models  of  temporal  lobe  epilepsy  (Joshi
t  al.,  2011).
Ganaxolone  has  anticonvulsant  and  protective  activ-
ty  in  diverse  rodent  seizure  models,  including  clonic
eizures  induced  by  the  chemoconvulsants  pentylenetetra-
ol,  bicuculline,  ﬂurothyl,  tert-butylbicycloorthobenzoate,
minophylline;  limbic  seizures  in  the  6  Hz  model;  amygdala
nd  cocaine-kindled  seizures;  and  corneal  kindled  seizures
see  Bialer  et  al.,  2010  and  Reddy  and  Rogwski,  2012).
n  female  amygdala  kindled  mice,  ganaxolone  produced
 dose-dependent  suppression  of  behavioral  and  electro-
raphic  seizures  (Reddy  and  Rogawski,  2010). In  chronically
reated  rats,  tolerance  does  not  occur  to  the  anticonvulsant
ctivity  of  ganaxolone  (Reddy  and  Rogawski,  2000).
oxicology  and  safety  pharmacology
here  was  little  evidence  of  target  organ  or  systemic  toxic-
ty  associated  with  either  single-  or  multiple-dose  treatment
ith  ganaxolone  (6  months  in  rat  and  1  year  in  dog)  (Marinus
harmaceuticals,  data  on  ﬁle).  Hematologic  or  serum  chem-
stry  parameters  were  not  altered,  and  no  anatomic  changes
ere  observed.  Ganaxolone  was  not  teratogenic  in  rats  and
ice  and  did  not  signiﬁcantly  affect  the  development  of
ffspring.  Speciﬁcally,  there  were  no  effects  on  fertility  or
mbryofetal  development  in  rats  at  doses  of  40  mg/kg/day,
nd  there  were  no  effects  on  peri-postnatal  development
xcept  a  slight  decrease  in  body  weight  (up  to  6%)  at  this
ose.  In  a  neonatal  rat  study  at  a  dose  of  50  mg/kg/day,
o  adverse  effects  were  obtained.  In  mice,  no  effects  on
mbryofetal  development  were  demonstrated  at  a  higher
ose  of  300  mg/kg/day.  Ganaxolone  also  showed  no  poten-
ial  for  mutagenicity  or  carcinogenicity.  In  studies  performed
o  assess  central  nervous  system  behavioral  effects  in  mice,
anaxolone  showed  less  of  an  interaction  with  ethanol  than
id  valproic  acid  in  the  hanging  wire-mesh  test  of  ataxia  and
anaxolone  affected  cognitive  function  in  an  animal  passive-
voidance  paradigm  only  at  doses  causing  ataxia.  Dosing  in
oxicology  and  safety  studies  was  limited  only  by  sedation
nd,  in  rodents,  by  liver  weight  gain  associated  with  CYP
nduction.
linical  pharmacokinetics
anaxolone  is  a  lipophilic,  high  clearance  compound.  After
dministration  of  a  single  dose  of  ganaxolone,  plasma  levels
apidly  decline  due  to  metabolism  and  tissue  distribution
ollowed  by  a  longer  elimination  phase.  Multiple  dosing
ith  the  ganaxolone  capsule  formulation  achieved  steady
tate  within  48  h  when  ganaxolone  was  dosed  200,  400,  or
00  mg  b.i.d.  with  a  standard  meal  or  snack,  and  the  effec-
ive  half-life  was  7—10  h.  Mean  peak  plasma  concentrations
Cmax)  and  AUC(0—12) at  steady-state  were  close  to  dose-
roportional  (Marinus  Pharmaceuticals,  data  on  ﬁle;  Bialer
t  al.,  2010).Because  of  its  aqueous  insolubility,  formulation-
ependent  food  effects  have  been  observed  where
bsorption  is  higher  in  the  fed  than  in  the  fasted  state.  To
nhance  its  bioavailability,  ganaxolone  has  been  formulated
g
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n a  nanosized  particulate  suspension  and  a  nanosized
articulate  capsule.  The  capsule  formulation  at  a  400  mg
ose  gave  approximately  2-fold  higher  AUC  and  3-fold
igher  Cmax  levels  in  a high-fat  fed  state  compared  to
he  fasted  state.  Based  on  Cmax,  AUC  and  trough  levels  at
teady  state,  400  to  600  mg  b.i.d.dosing  of  the  ganaxolone
apsule  formulation  provides  comparable  ganaxolone
xposure  to  500  mg  t.i.d.  dosing  of  the  suspension  formu-
ation  (Marinus  Pharmaceuticals,  data  on  ﬁle;  Bialer  et  al.,
010).
rug  interactions
esults  of  a  midazolam  interaction  study  (1042-0402)  in  nor-
al  volunteers  with  the  capsule  formulation  of  ganaxolone
osed  400  mg  b.i.d.  for  12  days  indicated  that  ganaxolone
s  not  a  CYP3A4  inhibitor  and  showed  low  or  no  potential  to
nduce  CYP3A4  metabolism  (<30%  change  in  midazolam  phar-
acokinetic  parameters  comparing  pre-ganaxolone  dosing
ersus  concomitant  ganaxolone  dosing  at  steady  state).  This
esult  is  consistent  with  in  vitro  studies  showing  that  ganax-
lone  has  low  potential  to  affect  the  disposition  of  other
rugs.  However,  data  from  the  1042-0600  study  did  show
ffects  of  concomitant  administration  of  strong  CYP3A4
nducers  (carbamazepine  and  phenytoin)  on  ganaxolone
harmacokinetics  (approximately  40%  higher  ganaxolone
learance  than  coadministration  with  other  AEDs).  In  vitro
tudies  have  shown  that  the  CYP3A4  inhibitor  (ketoconazole)
locks  the  metabolism  of  ganaxolone  (Marinus  Pharmaceut-
cals,  data  on  ﬁle).
linical  efﬁcacy
rior  to  being  acquired  by  the  current  sponsor,  ganaxolone
as  studied  in  three  open-label  pediatric  studies  and  a
ouble-blind  randomized  pre-surgical  study  in  adults  and
hildren  with  seizure  disorders  (Laxer  et  al.,  2000;  Kerrigan
t  al.,  2000;  Pieribone  et  al.,  2007). A  double-blind  ran-
omized  trial  in  infantile  spasms  (West  Syndrome)  under
he  current  sponsor  was  reported  previously  (Bialer  et  al.,
010).
The  current  sponsor  has  also  completed  a  double-
lind,  placebo-controlled  study  of  ganaxolone  (1042-0600)
s  adjunctive  therapy  in  adults  with  POS,  which  was  orig-
nally  reported  in  the  summary  from  Eilat  X  (Bialer  et  al.,
010);  additional  information  from  a  follow-on  open  label
xtension  study  is  reported  here.  In  the  double-blind  study,
dult  subjects  aged  18—69  years,  with  POS  with  or  without
econdary  generalization  refractory  to  conventional  AEDs
ere  randomized  in  a  2:1  ratio  to  receive  ganaxolone  (n  =  98)
r  placebo  (n  =  47).  Baseline  seizure  frequency  per  28  days
as  6.5  in  the  ganaxolone  group  and  9.2  in  the  placebo
roup.  Mean  duration  of  illness  was  25  years,  and  75%  of  the
tudy  population  took  2  or  3  concomitant  AED  medications.
fter  an  8-week  baseline  period,  participants  were  titrated
o  1500  mg/day  (3  divided  doses  with  a 300  nm  nanosized
anaxolone  suspension  formulation)  over  a  1—2-week  period
nd  maintained  at  that  dose  for  an  additional  8  weeks.
ownward  dose  adjustments  were  permitted  if  necessary
ecause  of  tolerability.
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(Progress  report  on  new  antiepileptic  drugs  
In  this  double-blind  study,  ganaxolone  treatment  pro-
duced  an  18%  decrease  in  mean  weekly  seizure  frequency,
compared  with  a  2%  increase  for  placebo  over  the  10-week
treatment  period  (p  =  0.014).  Responder  rates  (proportions
of  subjects  with  greater  than  50%  reduction  in  seizures  dur-
ing  the  maintenance  phase)  were  26%  for  the  ganaxolone
group  versus  13%  for  placebo  (p  =  0.057).  Of  131  completers,
94%  entered  a  104-week  open-label  extension  study.
The  objective  of  the  open-label  extension  was  to  eval-
uate  the  long-term  safety,  tolerability  and  efﬁcacy  of
ganaxolone  at  a  target  dose  of  1500  mg/day.  Subjects  were
dosed  for  a  mean  of  274  days  (39  weeks).  Most  subjects
(89%)  reached  1500  mg/day  and  72%  were  maintained  on
this  dose  before  tapering.  Thirty-eight  subjects  (30%)  com-
pleted  more  than  52  weeks  of  treatment  before  the  study
was  terminated  for  administrative  reasons.
Efﬁcacy  in  the  open-label  extension  study  was  reported
as  the  median  and  mean  change  in  weekly  seizure  frequency
at  endpoint  compared  to  the  baseline  from  the  beginning  of
the  double-blind  study.  For  all  subjects  at  endpoint,  median
and  mean  improvement  in  weekly  seizure  frequency  were
23%  and  14%  respectively.  Subjects  previously  randomized
to  ganaxolone  (n  =  79)  in  the  double-blind  study  had  median
improvement  in  weekly  seizure  frequency  of  14%  at  end-
point  while  those  randomized  to  placebo  had  median  weekly
seizure  frequency  improvement  of  35%  (n  =  41).  Twenty-four
percent  of  all  subjects  met  responder  criteria  (50%  improve-
ment)  at  endpoint,  29%  having  originally  been  randomized
to  placebo  and  22%  having  been  randomized  to  ganaxolone.
Tolerability  and  safety  in  clinical  studies
More  than  900  adults  and  children  have  been  exposed  to
ganaxolone  in  Phase  I  and  Phase  II  studies.  The  drug  was
found  to  be  generally  safe  and  well-tolerated  at  the  doses
used  (for  Phase  II  studies,  up  to  1875  mg/day  in  adults  and
up  to  54  mg/kg/day  in  infants).  Tolerability  and  safety  in
children  and  infants  has  been  described  previously  (Bialer
et  al.,  2009,  2010).
In  the  double-blind,  randomized  trial  described  above
(study  1042-0600)  in  147  adults,  TEAEs  reported  by  at  least
5%  of  patients  and  at  least  twice  as  common  in  the  ganax-
olone  group  versus  the  placebo  group  were  dizziness,  fatigue
(both  16%  versus  8%)  and  somnolence  (13%  versus  2%).  Seven
percent  of  ganaxolone  subjects  and  6%  of  placebo  subjects
discontinued  treatment  due  to  TEAEs.  There  were  no  deaths
during  the  study,  and  serious  TEAEs  occurred  in  5%  of  ganax-
olone  versus  8%  of  placebo  treated  subjects.  No  clinically
important  trends  were  seen  in  clinical  laboratory  tests,  elec-
trocardiograms  (ECGs),  vital  signs  or  body  weight.
Ganaxolone  continued  to  be  safe  and  well  tolerated  in
the  open-label  extension  study.  TEAEs  reported  in  greater
than  10%  of  subjects  were  headache  (21%),  convulsion
(16%),  fatigue  (16%),  fall  (14%),  nasopharyngitis  (14%),  dizzi-
ness  (13%),  contusion  (12%),  nasal  congestion  (10%).  Serious
TEAEs  were  reported  in  14%  of  subjects,  and  8%  were  not
related  to  the  underlying  disease.  Median  weight  change
at  endpoint  was  less  than  0.5  kg.  There  were  no  trends
of  important  changes  in  chemistry,  hematology,  vital  signs,
physical  and  neurological  examinations,  or  ECGs.  No  new
w
p
o
111
afety  concerns  were  identiﬁed  during  extended  treatment
ith  ganaxolone  for  up  to  104  weeks.
onclusions  and  ongoing  studies
ata  from  a  10-week,  double-blind,  placebo-controlled
tudy  of  ganaxolone  (1500  mg/day)  as  adjunctive  therapy  of
dults  with  treatment-refractory  POS  as  well  as  data  from
he  104-week  open-label  extension  study  show  the  drug  to
e  efﬁcacious,  safe  and  well-tolerated.  Importantly,  there
as  no  evidence  of  weight  gain  with  extended  exposure.
he  most  recent  clinical  trial  results  in  conjunction  with
everal  previous  studies  support  development  of  ganaxolone
or  the  adjunctive  treatment  of  POS.  Ganaxolone  represents
 new,  mechanistically  novel  AED.  The  clinical  information
vailable  indicates  that  the  drug  is  safe  in  all  infants,  pedi-
trics  and  adults.  Data  from  non-clinical  studies  suggest
hat  ganaxolone  may  have  low  risk  for  use  in  pregnancy.
herefore,  ganaxolone  has  the  potential  to  provide  impor-
ant  clinical  beneﬁt  to  subgroups  of  epilepsy  patients  who
urrently  have  limited  treatment  options.
Neurosteroids  have  also  been  proposed  for  study  in  a
road  range  of  neurological  and  psychiatric  conditions  apart
rom  epilepsy.  Therapeutic  utility  may  result  from  GABAA
eceptor  modulation  as  well  as  effects  on  neuronal  and  glial
ifferentiation,  myelination,  inﬂammation,  and  because  of
europrotective  properties.  Potential  additional  uses  of
anaxolone  are  being  explored  through  proof-of-concept
tudies  in  posttraumatic  stress  disorder  and  fragile  X  syn-
rome,  which  are  currently  in  progress.
CA-105665 (PF-04895162)
.  Roeloffs1, D.  S.  Krafte1, A.  C.  Gerlach1 and  G.  C.  Rigdon2
1Neusentis  (a  Pﬁzer  Inc.,  Research  Unit),  Durham,  NC  USA
2Halcyon  Drug  Development,  Inc.,  Wake  Forest,  NC  USA
ntroduction
CA-105665  (PF-04895162)  is  a  highly  selective  opener  of
euronal  Kv7  (KCNQ)  potassium  channels;  the  molecular
omponents  of  the  slow  voltage-gated  M  current  (Table  2).
ts  chemical  structure  has  not  yet  been  disclosed.  A  more
etailed  description  of  the  preclinical  pharmacology  and
oxicology  may  be  found  in  Bialer  et  al.,  2010. Clinical
ata  have  previously  been  presented  in  abstract  form  at
he  American  Epilepsy  Society  meetings  in  2009  and  2010
Hetherington  et  al.,  2009;  Rigdon  et  al.,  2009;  Risner  et  al.,
009,  and  Biton  et  al.,  2010).
harmacology
nticonvulsant  activity  in  animal  models
n  vivo,  ICA-105665  protects  against  maximal  electroshock
MES),  scMetrazol,  (scMet)  6  Hz  and  kindled  seizures
Tables  1  and  3).  In  tests  conducted  by  the  sponsor,  ED50s
ere  ≤1  mg/kg  for  s.c.  pentylentetrazol  and  MES.  The  com-
ound  did  not  affect  the  ability  of  rats  to  maintain  position
n  a  rotorod  at  doses  up  to  the  highest  dose  tested  (i.e.,
00  mg/kg  po).
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Table  2  Anticonvulsant  proﬁle  of  investigational  AEDs  in  rat  models.
Compound  Route  of
adminis-
tration
Time  of
test
(min)
ED50 (mg/kg)  TD50 (mg/kg)  In  vivo  activity  in  other  disease
model  systems  actions
MES  s.c.  PTZ  Kindled  rat  (i.e.,
corneal,  amygdala,
hippocampal)
Spike-wave
seizure  model
(GAERS,
Lethargic
mouse,  GHB
rat,  WAG/Ri
rat)
Behavioral
toxicity  (e.g.,
rotarod,
observational,
etc.)
Brivaracetam i.p. 60 N/A  N/A  44  mg/kg  (amygdala)  2.6  mg/kg
(GAERS)
163  mg/kg
(Kindled  rats)
177  mg/kg
(GAERS)
Self-sustaining  status  epilepticus
model  (perforant  path
stimulation);  diabetic  and  CCI
models  of  neuropathic  pain;  and
post-hypoxic  myoclonus
p.o. 60  N/A  N/A  45  mg/kg  (amygdala)  N/A  N/A
2-Deoxy-D-glucose  p.o.  15—240  No  effect  at
doses  up  to
200  mg/kg
Partial
protection  at
doses  upto
400  mg/kg,  p.o.
NT  NT  NT  Delays  the  acquisition  of  kindling
induced  by  perforant  path  or
olfactory  bulb  stimulation  at
doses  of  37.5—50  mg/kg;
neuroprotective  in  the  CCI  model
of TBI
Ganaxolone i.p.  30  7.8  N/A  4.5  (corneal)  NT  14.2
ICA-105665 p.o. 60  11  Max.  25%
protection  at
160  mg/kg
NT  NT  >500  Increases  latency  to  tonic
extension  in  MES  and  tonic-clonic
seizures  in  sc  PTZ  (ED50’s:  0.9  and
0.7 mg/kg,  respectively);  active  in
lamotrigine-resistant  kindled  rat
i.p. N.T.  N.T.  <3.8  mg/kg  in
hippocampal  rat
against  expression  of
seizures
N.T.
Imepition  (AWD
131—138  or  ELB
138)
p.o.  21  16  Increases
afterdischarge
threshold  at  doses  as
low as  1  mg/kg;
completely  inhibits
secondary
generalization  at
20  mg/kg,  i.p.
Effective  in
WAG  rat  model
of  generalized
absence  at
3  mg/kg,  p.o.
(98%
suppression  of
SWD  observed
at  30  mg/kg
p.o.
>400  Blocks  SWD  induced  by  25  mg/kg,
i.p. dose  of  PTZ  at  3  mg/kg,  p.o.;
Increases  the  PTZ  seizure
threshold  in  dogs  by  33—59%  after
repeated  oral  administration  of
5  mg/kg;  prolongs  kindling
acquisition  in  amygdala  kindled
rat when  administered  prior  to
kindling  stimulation
Progress
 report
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NAX  810-2 i.p.  0.25—24  hNT  NT  NT  NT  >4.0  mg/kg  Elevates  threshold  for  mechanical
allodynia  in  rat  sciatic  nerve  ligation
model  of  neuropathic  pain  at
4.0  mg/kg
Perampanel
(E2007)
p.o. 60 N.T. N.T. Increases
afterdischarge
threshold  and
decreases
afterdischarge
duration  at  10  mg/kg;
decreases  behavioral
seizure  score  and
motor  seizure
duration  at  5  and
10 mg/kg
No  effect  on
SWD  at  doses
between  1  and
10  mg/kg
9.14
SPD i.p. 15 20 62 19  mg/kg  fully
expressed
hippocampal  kindled
rat  secondarily
generalized  seizures
SNL-ED50 =  49  mg/kg
NT 49
p.o, 60 29 82  and  18
(30  min)
NT 131
Tonabersat p.o. 15—240  2.1 >250 Inactive  in
hippocampal  and
LTG-resistant  kindled
rat
NT >500 Dose-dependently  elevates  threshold
for tonic  extension  seizures  induced
by electroshock  and  s.c.  PTZ;  blocks
high K  +  bursting  in  rat  hippocampal
slices;  suppresses  neuron-glial
communication  via  gap  junctions;
inhibits  acute  and  chronic
inﬂammation-induced  expression  of
connexin-26
VCD p.o.  60  29
(racemate)
34  ((2R,3S)-
VCD)  64
((2S,3S)-
VCD)
54.  (racemate)
11
((2R,3S)-VCD)
33
((2S,3S)-VCD)
SNL-ED50 =  29  mg/kg  NT  >100  Racemate  and  isomers  of  VCD  were
found  to  be  active  against  tactile
allodynia  in  Cheung  model  of
neuropathic  pain
(2R,3S)-VCD i.p.  60  34  11  SNL-ED50 =  34  mg/kg
(2S,3S)-VCD  64  33  SNL-ED50 =  65  mg/kg
14  
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ICA-105665  was  also  tested  by  the  Anticonvulsant
creening  Project  of  the  National  Institute  of  Neurological
isorders  &  Stroke  (ASP-NINDS,  NIH).  In  mice,  ICA-105665
as  active  in  the  MES,  s.c.  pentylentetrazol,  6  Hz  psy-
homotor  seizures,  and  audiogenic  seizure  tests.  ICA-105665
levated  seizure  threshold  in  the  i.v.  pentylenetetrazol
ssay.  In  rats,  ICA-105665  did  not  produce  signs  of  toxic-
ty  by  the  minimal  motor  impairment  test  at  p.o.  doses  up
o  500  mg/kg.  It  protected  against  MES-induced  tonic  exten-
ion  seizures  and  was  active  in  the  hippocampal  kindled  rat
odel  of  POS.  ICA-105665  was  also  active  in  the  lamotrigine-
esistant  amygdala  kindled  rat  model  of  pharmacoresistant
pilepsy).
echanism  of  action
CA-105665  opens  cloned  human  neuronal  Kv7  channels  with
C50’s  of  0.3  M  (Kv7.2/7.3),  1.5  M  (Kv7.3/7.5)  and  3.3  M
Kv7.4).  ICA  105665  did  not  interact  with  a  variety  of  other
on  channels,  including  the  cardiac  ion  channels.
oxicology
afety  pharmacology,  6  month  rodent  and  9  month  non-
odent  toxicity,  as  well  as  reproduction  toxicity  and
enotoxicity  studies  required  to  meet  International  Con-
erence  on  Harmonization  (ICH)  guidelines  have  been
ompleted.  Common  ﬁndings  at  the  higher  doses  in  rodents
ave  included  decreased  body  weight  gain  and  food  con-
umption.  In  rodents  and  non-human  primates,  common
linical  signs  at  the  higher  doses  have  included  tremors,
taxia  and  hypoactivity.
linical  pharmacokinetics
n  healthy  volunteers,  ICA-105665  was  well-tolerated  follow-
ng  single  oral  doses  up  to  400  mg  and  multiple  doses  up  to
00  mg/day  (300  mg  b.i.d.).  The  compound  is  highly  bound
>99%)  to  plasma  proteins,  primarily  albumin.  Mean  half-life
alues  after  oral  administration  ranged  from  5  to  9.5  h  Phar-
acokinetics  were  linear  after  single  and  repeated  doses,
ith  area  under  the  plasma  concentration-time  curve  (AUC)
nd  Cmax values  increasing  approximately  in  proportion  to
ose.  In  14  patients  with  epilepsy  treated  with  100  and
00  mg  b.i.d.  for  7  days,  the  mean  half-life  of  ICA-105665
as  similar  to  that  found  in  healthy  volunteers.
rug  interactions
ormal  drug  interaction  studies  have  not  been  conducted.
CA-105665  at  concentrations  up  to  30  M  (highest  concen-
ration  tested)  did  not  inhibit  CYP  enzymes  or  P-glycoprotein
ediated  transport,  and  studies  conducted  using  fresh
uman  hepatocytes  indicate  it  is  unlikely  to  induce  liver
nzymes.arly  Phase  II  study
o  establish  that  ICA-105665  penetrates  the  blood-brain
arrier  and  engages  neuronal  Kv7  channels,  its  ability  to
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iProgress  report  on  new  antiepileptic  drugs  
reduce  the  photoparoxysmal  EEG  response  was  investigated
in  epilepsy  patients  with  photosensitivity,  using  standard-
ized  methods  (Kasteleijn-Nolst  Trenité  et  al.,  1996). Cohorts
of  4—6  subjects  (100,  200,  400  and  500  mg  single  dose)  were
tested,  with  a  single  subject  being  tested  at  600  mg  (Clinical-
Trials.gov  identiﬁer:  NCT00979004).  Subjects  were  exposed
to  photic  stimulation  (2—60  ﬂashes  per  second)  1—28  h  after
a  single  oral  dose  of  placebo  on  Day  1  and  ICA-105665  on
Day  2.  A  single  blind  design  was  used;  investigators  and
sponsor,  but  not  subjects,  were  aware  of  treatment  assign-
ment.  Decreases  in  the  photosensitivity  range  (deﬁned  as  a
reduction  in  the  standard  photosensitivity  range  of  at  least
3  frequency  steps  at  three  or  more  hourly  measurements
after  dosing,  compared  to  the  time-matched  assessments
on  Day  1)  occurred  in  1of  4  subjects  at  100  mg,  2  of  4
subjects  at  400  mg,  and  4  of  6  subjects  at  500  mg  The
single  subject  that  received  600  mg  experienced  a  serious
TEAE  (see  below)  before  undergoing  photic  stimulation.
One  of  the  tested  subjects  had  a  signiﬁcant  reduction  in
photoparoxysmal  responses  after  a  100  mg  dose  and  a  com-
plete  abolishment  of  response  2  h  after  a  400  mg  dose.  The
duration  of  response  appeared  to  increase  with  dose.  One
patient  in  the  400  mg  cohort  and  2  patients  in  the  500  mg
cohort  maintained  partial  suppression  of  photosensitivity  for
>20  h
Tolerability  and  adverse  event  proﬁle
Three  Phase  I  studies  focused  on  safety  and  pharmacokinetic
parameters  demonstrated  good  tolerability  and  potential  for
b.i.d.  dosing  without  titration.  In  these  studies,  healthy  vol-
unteers  tolerated  single  doses  up  to  400  mg  and  multiple
doses  up  to  600  mg/day  for  7  days;  subjects  with  epilepsy
tolerated  400  mg/day  in  2  divided  doses  for  7  days.  There
were  no  dose-limiting  toxicities,  severe  or  life-threatening
TEAEs,  serious  TEAEs,  or  discontinuations  due  to  TEAEs,  nor
were  there  important  trends  or  changes  from  baseline  for
clinical  laboratory,  vital  signs,  ECG,  or  physical  examination
ﬁndings.  The  most  common  TEAE  in  subjects  who  received
ICA-105665  was  headache.  Other  commonly  reported  TEAEs
were  generally  CNS-related,  including  dizziness  and  somno-
lence.  Dizziness  appeared  to  be  the  ﬁrst  TEAE  related  to
treatment.
In  the  Phase  II  study  in  photosensitive  epilepsy,  single
doses  of  ICA-105665  ranging  from  100  to  400  mg  were  well
tolerated.  The  500  mg  dose  was  associated  with  TEAEs  (espe-
cially  dizziness)  in  most  subjects  and  was  deﬁned  as  the
maximum  tolerated  dose.  A  single  subject  with  juvenile
myoclonic  epilepsy  and  a  history  of  generalized  tonic-clonic
seizures  received  a  single  600  mg  dose  of  ICA-105665  and
experienced  a  brief  tonic-clonic  seizure,  and  the  study  was
terminated.  The  patient  recovered  uneventfully  and  the  role
of  ICA-105665  in  the  event  was  not  clear.
Planned  studiesWith  the  acquisition  of  Icagen  by  Pﬁzer,  Inc.,  ICA-105665  is
now  formally  part  of  the  Pﬁzer  portfolio  and  future  clinical
studies  are  being  planned  by  the  new  project  team.
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Imepitoin (AWD131 -138 or ELB138)
Imepitoin  (AWD  131—138  or  ELB  138;  1-(4-chlorophenyl)-
-morpholino-imidazolin-2-one)  is  a  new  chemical  entity
hat  was  previously  presented  at  the  EILAT  IV  and  V  con-
erences  (Bialer  et  al.,  1999,  2001). It  was  developed  in
he  1990s  from  a  series  of  imidazolinones  by  Asta  Medica
nd  Arzneimittelwerk  Dresden  (AWD;  later  Elbion,  Rade-
eul,  Germany)  (Rostock  et  al.,  1998a). Furthermore,  it
as  tested  in  the  NINDS-sponsored  Anticonvulsant  Screening
roject  (ASP).  Imepitoin  was  selected  for  further  devel-
pment  because  of  its  broad  spectrum  of  anticonvulsant
ctivity,  high  therapeutic  index,  and  its  efﬁcacy  in  tests
redictive  for  anxiolytic  effects.  It  underwent  Phase  I clin-
cal  studies,  but  further  clinical  development  for  humans
as  suspended.  However,  interesting  ﬁndings  in  dogs  (see
elow)  led  Boehringer  Ingelheim  (Germany)  to  the  decision
o  develop  imepitoin  as  a  new  AED  for  canine  epilepsy.
harmacology
nticonvulsant  activity  in  animal  models
mepitoin  is  active  in  primary  screening  tests  for  anticonvul-
ant  activity  in  mice  and  rats  using  the  maximal  electroshock
est  (MES)  and  supramaximal  stimulation  with  chemical
onvulsants  such  as  pentylenetetrazol  and  bicuculline.
udiogenic  clonic  seizures  in  genetic  models  of  epilepsy
re  potently  inhibited,  with  ED50 values  of  2.6  mg/kg  i.p.  in
BA/2  mice  and  5.0  mg/kg,  i.p.  in  Frings  mice.  In  addition,
mepitoin  elevates  the  chemically-induced  seizure  threshold
n  the  i.v.  pentylenetetrazol  test  in  mice.  It  also  increases
he  pentylenetetrazol-induced  seizure  threshold  in  dogs
fter  single  doses  and  after  prolonged  oral  treatment  with  5
r  40  mg/kg  b.i.d.  (Löscher  et  al.,  2004). In  the  MES  thresh-
ld  test  in  mice,  imepitoin  elevates  the  threshold  for  tonic
indlimb  extension  after  i.p.  and  p.o.  doses,  starting  at  30
nd  50  mg/kg,  respectively  (Rostock  et  al.,  1998a;  Tober
t  al.,  1998,  1999;  Bialer  et  al.,  1999). Imepitoin  also  exerts
ronounced  anticonvulsant  effects  in  models  for  partial
nset  seizures.  In  fully  amygdala-kindled  rats,  the  threshold
or  induction  of  afterdischarges  is  increased  dose  depend-
ntly,  with  signiﬁcant  effects  being  already  detectable  at
 mg/kg  i.p.,  the  lowest  dose  tested.  Starting  at  10  mg/kg
.p.,  imepitoin  inhibits  seizure  severity  after  electrical  stim-
lation  at  the  elevated  afterdischarge  threshold  current,
hereas  secondary  generalization  of  the  evoked  kindled
eizure  is  completely  inhibited  at  20  mg/kg  i.p.  Repeated
reatment  once  daily  with  imepitoin  during  kindling
16  M.  Bialer  et  al.
Table  3  Proposed  mechanisms  of  action  of  investigational  AEDs  currently  in  development.
Compound  Proposed  mechanism(s)  of  action
Brivaracetam  Binds  to  SV2A  (IC50 =  0.08  M)  and  inhibits  voltage-dependent  sodium  channels
(IC50 =  7  M;  max.  effect:  65%)
2-Deoxy-D-glucose  Inhibits  glycolysis;  suppresses  in  vitro  burst  discharges  induced  by  high  potassium,
4-aminopyridine,  bicuculline,  and  the  mGluR1  agonist  DHPG;  blocks  kindling
acquisition  by  repressing  expression  of  BDNF  and  TrKB
Ganaxolone  Directly  activates  and  allosterically  modulates  GABAA receptors  at  GABAA receptors
containing  a   subunits
ICA-105665 Selective  activator  of  neuronal  KCNQ  (Kv7)  potassium  channels
Imepitoin (AWD  131—138  or  ELB  138)  Low-afﬁnity  partial  agonist  at  the  benzodiazepine  (BZD)  recognition  site  of  the  GABAA
receptor
NAX 810-2  Enhances  galanin  receptor  neurotransmission  by  preferential  activation  of  GalR2
receptors
Perampanel (E2007)  Non-competitive  antagonist  of  AMPA-mediated  glutamate  receptors
sec-Butyl-propylacetamide  (SPD)  Unknown
Tonabersat  Novel  brain-speciﬁc  binding  site:  suppresses  neuron-glial  communication  via  gap
junctions;  inhibits  acute  and  chronic  inﬂammation-induced  expression  of  connexin-26
Valnoctamide  (VCD)  Inhibits  myo-inositol-1-phosphate  synthase,  unknown  anticonvulsant  and  antiallodynic
mechanism  of  action
VX-765  Anti-inﬂammatory;  selective  and  reversible  inhibitor  of  interleukin-converting  enzyme
YKP 3089  Unknown
SV2A, synaptic vesicle protein 2A; IC50, inhibitory concentration to produce 50% inhibition; M, micromolar; mGluR1, metabotropic
glutamate receptor subtype 1; AMPA, (-amino-3-hydroxy-5-5methyl-4-isoxazole propionic acid; BDNF, brain-derived neurotrophic factor;
TrKB, tyrosine kinase B (high-afﬁnity catalytic receptor for several neurotrophins including BDNF and neurotrophin 3 and 4); Nav, sodium
channel isoform; GABAA, -aminobutyric acid receptor; N-type, neuronal voltage-sensitive calcium channel; P/Q-type, purkinje/Q-type
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valnoctamide.
cquisition  delays  signiﬁcantly  the  development  of  gener-
lized  motor  seizures  at  20  and  30  mg/kg  i.p.  Imepitoin
ecreases  the  number  and  duration  of  spontaneous  spike-
ave  discharges  in  WAG  rats,  a  model  for  absence  epilepsy
lready  at  3  mg/kg  p.o.,  the  lowest  dose  tested.  After
dministration  of  30  mg/kg  p.o.,  spikes  and  waves  are
lmost  completely  suppressed  (98%  inhibition  of  number  and
uration  of  discharges).  In  addition,  imepitoin  at  a dose
f  3  mg/kg  p.o.  inhibits  the  number  and  total  duration  of
pikes  and  waves  induced  by  i.p.  administration  of  25  mg/kg
entylentetrazol  (Tober  et  al.,  1999).
During  repeated  administration,  no  evidence  of  tol-
rance  (i.e.  no  reduction  of  anticonvulsant  activity)  has
een  found  in  rodents  and  dogs,  even  when  very  high  doses
ere  given  (Rostock  et  al.,  1998b;  Tober  et  al.,  1998;
öscher  et  al.,  2004). In  particular,  during  29  days  of  oral
reatment  at  100  mg/kg  in  mice,  no  decrease  in  the  effect
n  the  MES  threshold  was  observed.  In  further  experiments
n  mice,  activity  in  the  MES  test  was  not  reduced  after
dministration  of  100  mg/kg  i.p.  b.i.d.  for  5  days.  In  the
ES  test  with  supramaximal  stimulation  in  rats,  no  change
n  anticonvulsant  activity  was  seen  after  administration  of
8  and  100  mg/kg  p.o.  for  5  days  (Rostock  et  al.,  1998b;
ober  et  al.,  1998;  Bialer  et  al.,  1999). In  dogs,  activity
n  the  pentylenetetrazol  seizure  threshold  test  remained
table  during  treatment  with  5  mg/kg  or  40  mg/kg  b.i.d.
.o.  for  4  weeks  (Löscher  et  al.,  2004).ctivity  proﬁle  in  models  of  anxiolytic  activity
tarting  at  dosages  of  3  mg/kg  i.p.  and  p.o.,  imepitoin  is
ctive  in  mouse  and  rat  models  predictive  of  anxiolytic
o
o
bsensitive calcium channel; SPD, sec-Butyl-propylacetamide; VCD,
ctivity,  such  as  innate  fear  and  fear  induced  by  open  and
igh  areas,  light  stimulation  and  unfamiliar  animals  (ele-
ated  maze,  light—dark  chamber,  social  interaction  test).  In
unishment  tests,  anxiety  was  clearly  decreased  only  in  the
ogel  conﬂict  test  in  rats  (Rostock  et  al.,  1998b).
echanism  of  action
mepitoin  acts  as  a low-afﬁnity  partial  agonist  at  the  ben-
odiazepine  recognition  site  of  the  GABAA receptor  (Rostock
t  al.,  1998a;  Sigel  et  al.,  1998). At  10  M,  GABA  currents  are
timulated  to  10—20%  of  the  maximal  stimulation  achieved
sing  diazepam.  The  threshold  of  stimulation  is  about
.3—1.0  M.  The  GABA-potentiating,  anxiolytic,  and  anti-
onvulsant  effects  of  imepitoin  could  be  counteracted  by
he  benzodiazepine  antagonist  ﬂumazenil,  indicating  that
he  interaction  of  imepitoin  with  the  benzodiazepine  site
ay  be  the  main  mechanism  of  action  of  this  novel  drug.
One  major  disadvantage  of  drugs  acting  via  the  ben-
odiazepine  site  of  GABA  receptors  is  their  tolerance,
ependence,  and  abuse  liability.  Partial  agonists  at  this  site
ave  been  suggested  to  offer  advantages  over  full  agonists  in
his  regard  (Löscher  et  al.,  1990;  Costa  and  Guidotti,  1996;
ehta  and  Ticku,  1999). In  line  with  this  suggestion,  imepi-
oin  failed  to  produce  benzodiazepine-like  discriminative
ffects  and  drug  self-administration  behavior  when  tested
n  squirrel  monkeys  (Yasar  et  al.,  2003). Furthermore,  no
oss  of  anticonvulsant  efﬁcacy  during  prolonged  treatment
r  withdrawal  symptoms  on  termination  of  treatment  were
bserved  in  mice  or  dogs  (Löscher  et  al.,  2004).
In  addition  to  its  effects  on  GABAA receptors,  imepitoin
locks  voltage-activated  Ca2+ channels  in  a  dose-dependent
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manner  (Bialer  et  al.,  1999). A  signiﬁcant  block  is
found  at  1  M,  and  it  is  as  yet  unclear  which  channel
subtype  is  affected.  Imepitoin  (1  and  100  M)  also  antag-
onizes  the  increased  ﬁring  of  action  potentials  induced  by
corticotrophin-releasing  factor  (CRF)  in  locus  coeruleus  neu-
rons  of  murine  brain  stem  slices.  This  effect  could  contribute
to  the  anxiolytic  activity.  Imepitoin  has  no  effects  on  the
normal  frequency  of  action  potential  ﬁring  in  these  neurons.
Toxicology
The  TD50 for  motor  impairment  in  the  rotarod  test  is  about
1000  mg/kg,  p.o.  in  rats.  This  low  neurotoxicity  was  con-
ﬁrmed  in  kindled  rats  with  altered  susceptibility  to  CNS
adverse  effects.  The  protective  index,  calculated  as  the
ratio  between  the  TD50 in  the  rotarod  test  and  the  dose
inducing  anticonvulsant  and  anxiolytic  activity  (3  mg/kg),  is
333  in  rats  after  p.o.  administration.  Consistent  with  the
low  neurotoxicity,  imepitoin  showed  no  measurable  effects
on  basal  synaptic  transmission  in  rat  brain  slices  with  ortho-
dromically  evoked  population  spikes  (Dost,  unpublished
results).
Pharmacokinetics
Imepitoin  is  absorbed  rapidly  and  extensively  in  rats  and
dogs,  and  shows  a  high  metabolic  stability  when  tested
in  vitro  with  human  liver  microsomes  and  human  liver  slices
(Bialer  et  al.,  1999). Elimination  half-lives  in  rats  and  dogs
were  dose-dependent,  ranging  from  1.1  to  6  h  (Bialer  et  al.,
1999;  Löscher  et  al.,  2004).
Efﬁcacy  and  tolerability  in  dogs  with  epilepsy
Epilepsy  is  the  most  common  chronic  neurological  disease  in
dogs  (about  0.6—1%  of  the  dog  population)  (Löscher  et  al.,
1985;  Podell,  1996). Currently,  there  is  only  one  licensed
AED  for  treatment  of  epileptic  dogs,  i.e.,  phenobarbital.
Most  other  AEDs  have  too  short  half-lives  in  dogs  (Frey  and
Löscher,  1985). About  70—80%  of  all  dogs  with  epilepsy  are
not  controlled  by  phenobarbital,  and  treatment  is  associ-
ated  with  adverse  effects  and  the  risk  of  severe  withdrawal
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eizures  upon  termination  of  treatment.  Thus,  new  treat-
ents  for  canine  epilepsy  are  urgently  needed.
Based  on  the  dose-ﬁnding  experiments  in  a  pentylen-
etrazol  seizure  model  in  dogs,  b.i.d.  oral  dosing  with
mepitoin  10—30  mg/kg  was  used  for  ﬁrst  exploratory
linical  trials  in  dogs  with  epilepsy  (Löscher  et  al.,
004).  In  a  prospective  trial  in  dogs  with  newly  diag-
osed  epilepsy,  monotherapy  with  imepitoin  markedly
educed  seizure  frequency  and  severity  without  signif-
cant  difference  to  standard  treatments  (phenobarbital
r  primidone),  but  was  much  better  tolerated  than  the
tandard  drugs.  In  dogs  with  chronic  epilepsy,  most  dogs
xhibited  a  reduction  in  seizure  frequency  and  severity
uring  add-on  treatment  with  imepitoin  (Löscher  et  al.,
004).
Overall,  the  data  in  dogs  demonstrate  that  the  par-
ial  benzodiazepine  receptor  agonist  imepitoin  exerts
igniﬁcant  anticonvulsant  efﬁcacy  without  tolerance  in
 dog  seizure  model  as  well  as  in  epileptic  dogs  with
pontaneously  recurrent  seizures.  These  data  thus  sub-
tantiate  that  partial  agonism  at  the  benzodiazepine  site
f  GABAA receptors  offers  advantages  versus  full  ago-
ism  and  constitutes  a  valuable  approach  for  treatment  of
eizures.
Based  on  these  data,  two  large  prospective  and  con-
rolled  multicenter  trials  were  performed  in  epileptic  dogs
y  Boehringer  Ingelheim.  The  trials  conﬁrmed  the  efﬁ-
acy  and  tolerability  of  imepitoin  as  a  new  AED  for  canine
pilepsy.  Currently,  imepitoin  (Pexion®)  is  in  late  stage
evelopment.
AX 810-2
.  Bulaja,  B.D.  Kleinb,c,  C.S.  Metcalfb, D.  McDougleb,  M.D.
mithc,  L.Zhanga,  H.S.  Whiteb,c
a Department  of  Medicinal  Chemistry,  University  of  Utah,
alt  Lake  City,  UT,  USA
bNeuroAdjuvants,  Inc.  Salt  Lake  City,  UT,  USA
cDepartment  of  Pharmacology  and  Toxicology,  University
f  Utah,  Salt  Lake  City,  UT,  USA
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ntroduction  and  rationale  for  development
alanin  has  been  recognized  as  a  potential  anticonvulsant
europeptide  since  the  early  work  of  Mazarati  and  cowork-
rs  (Mazarati  et  al.,  1992;  Mazarati  et  al.,  1998,  2000).
alanin  is  one  of  several  neuropeptides  with  demonstrated
nticonvulsant  activity  (Robertson  et  al.,  2010). Galanin  is
resumed  to  exert  its  biological  activity  through  the  acti-
ation  of  galanin  receptor  (GalR)  subtypes  1  and  2;  both
f  which  are  widely  expressed  in  the  CNS  (Lang  and  Koﬂer,
011).  Early  evidence  demonstrating  an  the  importance  of
oth  receptor  types  came  from  studies  conducted  in  GalR1
nockout  mice  and  in  rats  employing  a  GalR2  antisense
pproach  (Mazarati  et  al.  2004a,b,  2006;  Mazarati  and  Lu,
005).
The  development  of  galanin  as  an  AED  has  been  ham-
ered  by  its  marginal  metabolic  stability  and  inability  to
enetrate  the  blood-brain-barrier  when  delivered  systemi-
ally.  Further,  activation  of  peripheral  GalR1  results  in  the
nhibition  of  insulin  release  and  subsequent  hyperglycemia.
odiﬁcation  of  the  galanin  backbone  led  to  the  identiﬁca-
ion  of  a  series  of  metabolically  stable,  blood-brain-barrier
enetrant  novel  galanin  agonists  that  demonstrate  anti-
onvulsant  activity  following  systemic  administration  (Bulaj
t  al.,  2008;  Zhang  et  al.,  2009). The  ﬁrst  candidate  galanin
nalog  to  be  extensively  evaluated  was  the  GalR1-receptor
referring  analog  NAX  5055  (Bialer  et  al.,  2010). NAX  5055
as  found  to  possess  long-lasting  and  dose-dependent  activ-
ty  in  the  6  Hz  seizure  model  following  i.v.,  i.p.  s.c.  and
ral  administration  (White  et  al.,  2009). NAX  5055  also
xhibited  potent  efﬁcacy  in  other  models  of  epilepsy  and
ain.  Unfortunately,  NAX-5055  was  subsequently  shown  to
roduce  marked  hyperglycemia  that  was  associated  with
nhibition  of  insulin  release.  Subsequent  investigations  led
o  the  discovery  of  NAX  810-2,  a  GalR2-preferring  galanin
gonist  that  displays  similarly  potent  anticonvulsant  activity
n  a  battery  of  animal  seizure  and  epilepsy  models  (Table  1).
harmacology
tructure—activity  relationship  studies  demonstrated  that
he  N-terminal  fragment  GAL(1—16)  retains  potent  agonist
ctivity  at  hippocampal  galanin  receptors.  Based  on  that
nowledge,  the  following  modiﬁcations  were  introduced  to
he  GAL(1—16)  analogs:  (1)  the  Gly1  residue  was  replaced
y  sarcosine  as  N-methylation  of  Gly1  maintains  nanomolar
alanin  receptor  afﬁnity,  but  with  an  ∼15-fold  preference
or  GalR1  compared  to  GalR2.  (2)  ‘‘atom  shaving’’  of  this
-terminus  substantially  decreases  GalR1  afﬁnity  while  pre-
erving  relatively  high  GalR2  afﬁnity  (3)  residues  following
ritical  Tyr9  were  replaced  by  a  combination  of  Lys  residues
nd  lipoamino  acids,  such  as  lysine-conjugated  to  long-chain
arboxylic  acids  (Bulaj  et  al.,  2008;  Zhang  et  al.,  2009;
obertson  et  al.,  2010).
For  lead  optimization  studies,  approximately  40  new
nalogs  targeting  GalR2  were  chemically  synthesized  on  a
olid  support  using  standard  Fmoc  protocols  and  an  auto-
ated  peptide  synthesizer.  The  peptides  were  puriﬁed  by
eversed-phase  HPLC  separations  and  their  identities  were
onﬁrmed  by  mass  spectrometry.  The  new  series  of  analogs
ere  screened  for  anti-seizure  activity  in  the  mouse  6  Hz
h
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2  mA  test  following  i.p.  administration.  NAX  810-2  is  an  ini-
ial  lead  analog  from  this  series  that  has  undergone  extended
harmacologic  characterization.
nticonvulsant  proﬁle  in  experimental  models
s  shown  in  Table  1,  NAX  810-2  is  potently  active  at  both
he  32  and  44  mA  stimulation  intensities  in  the  mouse  6  Hz
eizure  model  following  i.p.  administration  and  is  effective
n  blocking  sound-induced  seizures  in  the  Frings  audio-
enic  seizure-susceptible  mouse.  NAX  810-2  is  also  potently
ctive  (Table  1)  against  the  fully  expressed  seizure  in  the
orneal  kindled  mouse  model  of  partial  epilepsy  (Matagne
nd  Klitgaard,  1998). In  contrast,  it  is  inactive  at  substan-
ially  higher  doses  (i.e.,  20  mg/kg,  i.p.)  in  the  maximal
lectroshock  test.  In  this  respect,  NAX  810-2  displays  an
nticonvulsant  proﬁle  similar  to  the  GalR1  preferring  analog
AX  5055.  NAX  810-2  has  been  evaluated  in  the  rotarod  test
or  motor  impairment.  In  this  particular  test,  the  median
oxic  dose  was  estimated  to  be  greater  than  32  mg/kg,  i.p.
ielding  a  wide  protective  index  (PI  =  TD50/ED50) of  more  than
0-fold  for  NAX  810-2  with  the  6  Hz  (32  mA)  test.
As  mentioned  above,  NAX  810-2  retains  potent  activity
n  the  6  Hz  test  even  when  the  higher  stimulation  intensity
44  mA)  is  employed.  The  results  obtained  in  the  6  Hz  test
re  of  particular  interest  because  this  model  has  evolved  as
 useful  model  for  differentiating  potential  AEDs  for  treat-
ent  of  refractory  partial  epilepsy  (Barton  et  al.,  2001).
he  overall  prolife  of  NAX  810-2  in  seizure  models  is  unique
ompared  to  the  majority  of  approved  AEDs  and  most  closely
esembles  that  of  levetiracetam.  In  addition  to  its  anticon-
ulsant  activity,  the  GalR1  preferring  analog  NAX  505-5  is
ffective  in  rodent  models  of  acute  and  chronic  pain  (Bialer
t  al.,  2010). Similarly,  NAX  810-2  following  systemic  admin-
stration  is  potently  active  in  mouse  models  of  inﬂammatory
ain  (Table  1).  It  was  active  in  the  carrageenan  assay  and
oth  the  acute  and  chronic  phases  of  formalin-induced  pain
n  mice.  The  overall  activity  of  NAX  810-2  supports  the  con-
inued  evaluation  of  these  novel  systemically  active  analogs
argeting  GalR2  for  the  treatment  of  epilepsy  and  pain.
echanisms  of  action
s  described  previously  (Bialer  et  al.,  2010), the  GalR1  pre-
erring  analog  NAX  5055  displays  low  nanomolar  binding
fﬁnity  for  both  GalR1  and  GalR2  with  Ki  values  of  3.5  and
1  nM,  respectively.  In  contrast,  NAX  810-2  possesses  low
anomolar  binding  afﬁnity  for  GalR2  (Ki  value  31.7  nM)  com-
ared  to  GalR1  (Ki  value  494  nM).  Importantly,  the  GalR1
inding  afﬁnity  of  NAX  810-2  is  reduced  >100-fold  compared
o  the  GalR1-preferring  agonist  NAX  505-5.  Both  NAX  5055
nd  NAX  810-2  are  presumed  to  exert  their  antiepileptic
ffects  through  selective  interaction  with  these  G-protein
oupled  galanin  receptors.  Studies  in  rat  brain  slice  prepa-
ations  have  shown  that  galanin  inhibits  glutamate  release
Zini  et  al.,  1993). Further,  activation  of  GalR2  has  been
hown  to  produce  trophic  effects  in  dorsal  root  ganglion  neu-
ons  (Mahoney  et  al.,  2003) and  to  be  neuroprotective  in
ippocampal  neurons  (Elliott-Hunt  et  al.,  2007). Therefore,
 mechanistically  novel  therapy  targeting  GalR2  may  possess
isease  modifying  properties  though  these  neuroprotective
nd  anti-inﬂammatory  effects.
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Planned  studies
Ongoing  studies  will  further  deﬁne  the  efﬁcacy  and  safety
potential  of  NAX  810-2  and  other  leads  from  this  new  series
targeting  GalR2  for  the  treatment  of  pharmacoresistant  POS.
The  preclinical  development  of  a  lead  candidate  targeting
GalR2  is  being  advanced  through  IND  ﬁling  supported  by
funding  from  a  NINDS  U01  translational  research  grant.
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Introduction  and  rationale  for  development
Perampanel  (E2007)  is  an  orally  active,  non-competitive,
and  highly  selective  antagonist  of  the  glutamate  AMPA
receptor  (Hanada  et  al.,  2011). The  AMPA  receptor  is  a
ligand-gated  ion  channel  that  has  long  been  identiﬁed  as
a  rational  drug  target  for  epilepsy.  Excessive  glutamate
transmission  is  implicated  in  the  initiation  and  spread  of
seizures,  and  as  the  AMPA  receptor  mediates  the  majority  of
fast  synaptic  transmission  by  glutamate  it  is  theorized  that
an  AMPA  receptor  antagonist  will  have  anti-seizure  activity
(Rogawski  and  Loscher,  2004).
Perampanel  is  the  ﬁrst  AMPA  receptor  antagonist  to  be
submitted  for  regulatory  approval  for  any  indication.  It  is
supported  by  a  large  dataset,  from  Phase  I studies,  Phase
II  studies  in  patients  with  multiple  sclerosis,  Parkinson  dis-
ease,  neuropathic  pain  and  epilepsy,  and  a  large  Phase  III
program  in  patients  with  POS.  Through  this  program,  over
4600  subjects  have  been  exposed  to  perampanel  in  clinical
trials  (Eisai,  Data  on  File).
Pharmacology
Studies  reported  by  Hanada  et  al.  (Hanada  et  al.,  2011) have
demonstrated  that  perampanel  is  a  potent  AMPA  receptor
antagonist,  inhibiting  AMPA-mediated  Ca2+ currents  in  vitro
with  an  IC50 of  93  nM.  Perampanel  has  no  effect  on  NMDA-
receptor-mediated  currents  at  this  concentration;  a  small
inhibition  is  seen  at  300-times  this  concentration  (Hanada
et  al.,  2011).
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Further evidence  of  the  selectivity  of  perampanel  comes
rom  ligand-binding  studies,  where  perampanel,  at  a  rela-
ively  high  concentration  of  10  M,  did  not  inhibit  by  ≥50%
he  binding  of  ligands  to  86  different  cellular  targets  (Eisai,
ata  on  ﬁle).
Perampanel  is  thought  to  act  via  a non-competitive
allosteric)  mechanism,  binding  to  a  separate  site  on  the
MPA  receptor  from  the  glutamate-binding  site.  Rather  than
irectly  competing  with  glutamate  to  inhibit  its  binding  to
he  AMPA  receptor,  perampanel  binds  to  an  allosteric  site
nd  thereby  prevents  glutamate  from  opening  the  recep-
or.  In  support  of  this  allosteric  mechanism,  radiolabeled
erampanel  is  not  displaced  from  rat  forebrain  membranes
y  glutamate  or  AMPA  but  is  displaced  by  known  non-
ompetitive  AMPA  receptor  antagonists  (Hanada  et  al.,
011).
nticonvulsant  proﬁle  in  experimental  models
he  anti-seizure  effects  of  perampanel  across  a  range  of
nimal  models  were  reported  in  the  previous  Eilat  report
Bialer  et  al.,  2010) and  these  data  have  now  been  published
n  full  (Hanada  et  al.,  2011).
ther  pharmacological  properties
MPA  receptors,  when  activated,  drive  the  generation  of
xcitatory  post-synaptic  potentials  (EPSPs)  to  propagate
ction  potentials  through  networks  of  neurons.  It  is  inter-
sting,  therefore,  to  explore  the  effects  of  perampanel
n  neuronal  networks.  Perampanel  inhibits  AMPA-receptor
ediated  EPSPs  in  hippocampal  slices  with  no  effect  on
MDA-  or  kainate-receptor-mediated  EPSPs,  demonstrating
electivity  for  AMPA-type  glutamate  receptors  (Ceolin  et  al.,
012)
echanism(s)  of  action
erampanel,  as  noted  earlier,  reduces  the  ability  of  glu-
amate  to  activate  AMPA  receptors  via  a  non-competitive
echanism  (Hanada  et  al.,  2011). The  theoretical  pro-
ess  by  which  this  leads  to  clinical  anti-seizure  effects
s  by  attenuating  the  neuronal  hyperexcitability  that
haracterizes  epileptic  brain  regions.  Glutamate  is  the  pre-
ominant  excitatory  neurotransmitter  in  the  brain,  and
MPA  receptors  play  a  central  role  in  seizure  genera-
ion  and  spread  (Rogawski  and  Loscher,  2004). Currently
pproved  AEDs  predominantly  act  pre-synaptically  to  reduce
euronal  excitability  (e.g.  Na+ channel  blockers,  K+ chan-
el  openers),  reduce  neurotransmitter  release  (e.g.  Ca2+
hannel  blockers,  levetiracetam)  or  increase  GABAergic
nhibitory  controls  (benzodiazepines,  tiagabine,  vigabatrin).
n  contrast,  perampanel  acts  post-synaptically  to  decrease
xcitability  (Rogawski  and  Loscher,  2004).
One  theoretical  consequence  of  the  non-competitive
echanism  of  action  is  that  the  ability  to  inhibit  AMPA-
eceptor  activation  should  be  maintained  even  when
lutamate  concentrations  are  high  (as  occurs  during  seizure
ctivity).  In  contrast,  a  competitive  antagonist  would  be
ut-competed  and  displaced  from  the  glutamate-binding
ite  when  glutamate  concentrations  are  high,  and  com-
etitive  antagonism  is,  therefore,  surmountable  (Kenakin,
006).  The  clinical  implications  of  this  are  still  being  evalu-
ted.
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oxicology
here  have  been  no  further  toxicology  studies  since  those
eported  in  the  previous  report  (Bialer  et  al.,  2010).
harmacokinetics
he  pharmacokinetics  of  perampanel  in  healthy  volunteers
ere  described  in  the  previous  report  (Bialer  et  al.,  2010).
n  summary,  perampanel  has  a  long  half-life  (∼70—110  h),
s  metabolized  primarily  by  CYP3A4,  and  steady  state  is
chieved  in  14  days  with  once-daily  dosing  (Eisai,  Data
n  File,  Bialer  et  al.,  2010). Recently  presented  popula-
ion  pharmacokinetic  analyses  support  a  one-compartment
odel  and  indicate  slightly  lower  clearance  in  females  than
ales  (Laurenza  et  al.,  2011).
rug  interactions
n  a  population  pharmacokinetic  analysis,  using  pooled  data
rom  the  3  Phase  III  clinical  trials,  perampanel  had  no
ffect  on  the  clearance  of  other  AEDs  (Laurenza  et  al.,
011).  Clearance  of  perampanel  was  increased  2-fold  by
xcarbazepine  and  phenytoin  and  increased  3-fold  by  car-
amazepine  (Laurenza  et  al.,  2011).
There  is  a  positive  relationship  between  plasma  per-
mpanel  concentration  and  clinical  response.  As  average
xposure  to  perampanel  at  steady  state  increased,  seizure
requency  decreased  and  the  probability  of  an  individual
eing  a  responder  (≥50%  reduction  in  seizure  frequency)
ncreased  signiﬁcantly.  Concomitant  AEDs  had  no  effect  on
he  exposure/efﬁcacy  relationship  for  seizure  frequency  or
he  probability  of  response  at  any  given  plasma  concentra-
ion  (Laurenza  et  al.,  2011).
fﬁcacy  data
ata  from  perampanel  Phase  II  trials  were  reported
n  the  previous  Eilat  report  (Bialer  et  al.,  2010)
nd  have  now  been  published  (Krauss  et  al.,  2011).
harmacokinetic—pharmacodynamic  (PK/PD)  modeling  from
hese  Phase  II  trials  established  the  no  effect  dose
2  mg/day),  the  minimum  effective  dose  (4  mg/day),  the
id  effective  dose  (8  mg/day),  and  the  high  effective  dose
12  mg/day).
Results  from  three  Phase  III  trials  in  1480  subjects  have
een  presented  (Study  304:  French  et  al.,  2012a; Study
05:  French  et  al.,  2012b  and  Study  306:  Krauss  et  al.,
012).  These  trials  all  utilized  similar  trial  designs,  with  a
-week  baseline  period,  a  6-week  titration  period,  and  a  13-
eek  maintenance  period.  Patients  were  ≥12  years  of  age,
ith  refractory  POS,  and  already  taking  1—3  AEDs.  Unless
tated  otherwise,  data  are  reported  over  the  entire  19-week
ouble-blind  treatment  period  (titration  +  maintenance).
The  ﬁrst  study  to  be  reported  (306,  NCT00700310)
nvestigated  perampanel  at  doses  of  2,  4  and  8  mg/day
nd  placebo.  The  median  percent  change  from  base-
ine  in  seizure  frequency  was  signiﬁcantly  greater  with
 and  8  mg/day  perampanel  (−23.3%,  p  =  0.0026  and
30.8%,  p  <  0.0001,  respectively)  but  not  2  mg/day  (−13.6%)
g
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ompared  to  placebo  (−10.7%).  The  responder  rate  was
igniﬁcantly  higher  during  the  maintenance  period  in  the
roups  randomized  to  4  and  8  mg/day  perampanel  (28.5%,
 =  0.0132  and  34.9%,  p  =  0.0003,  respectively)  but  not
 mg/day  (20.6%)  compared  to  placebo  (17.9%)  (Krauss
t  al.,  2012).
The  next  two  studies  conﬁrmed  the  efﬁcacy  of  the
 mg/day  dose  and  also  included  a  higher  dose  (12  mg/day).
tudy  305  (NCT00699582)  demonstrated  a  signiﬁcant  reduc-
ion  in  seizure  frequency  with  perampanel  8  mg/day
median  percent  change  from  baseline:  −30.5%,  p  <  0.001)
nd  12  mg/day  (−17.6%,  p  =  0.011)  versus  placebo  (−9.7%),
nd  a  signiﬁcant  increase  in  responder  rate  (33.3%  at
 mg/day,  p  =  0.0018  and  33.9%  at  12  mg/day,  p  =  0.0006)
ersus  placebo  (14.7%)  (French  et  al.,  2012b).
Study  304  (NCT00699972)  also  demonstrated  a  signiﬁcant
eduction  in  seizure  frequency  with  perampanel  8  mg/day
median  percent  change  from  baseline:  −26.3%,  p  =  0.0261)
nd  12  mg/day  (−34.5%,  p  =  0.0158)  versus  placebo  (−21.0%)
ut  responder  rates  (37.6%  and  36.1%,  respectively)  were
ot  signiﬁcantly  greater  than  the  high  placebo  responder
ate  (26.4%)  (French  et  al.,  2012a). Placebo  rates  in  study
04  were  high,  particularly  in  Central  and  South  American
tudy  centers.  Responder  rates  with  perampanel  were  sig-
iﬁcantly  higher  than  with  placebo  in  the  North  American
enters,  but  not  the  Central  and  South  American  centers.
n  explanation  for  this  regional  difference  has  not  been
orthcoming  despite  extensive  analyses.
olerability  and  adverse  event  proﬁle
hase  II  studies  showed  that  perampanel  was  tolerated  at
oses  up  to  12  mg/day  (Krauss  et  al.,  2011), and  Phase  III
tudies  revealed  no  additional  safety  concerns.  In  the  ﬁrst
hase  III  study  (306),  the  most  common  TEAEs  (occurring  in
10%  of  patients  from  any  treatment  group)  were  dizziness
27%  with  8  mg/day  versus  10%  with  placebo),  somnolence
16%  versus  7%)  and  headache  (11%  versus  9%)  (Krauss  et  al.,
010).  Serious  TEAEs  were  not  more  frequent  with  study  drug
3.6%  with  8  mg/day)  than  with  placebo  (4.9%),  and  discon-
inuation  rates  due  to  TEAEs  were  low  (7.1%  with  8  mg/day
ersus  3.8%  with  placebo)  (Krauss  et  al.,  2012).
In studies  304  (French  et  al.,  2012a) and  305  (French
t  al.,  2012b), similar  TEAEs  were  seen,  and  rates  were  gen-
rally  higher  with  12  mg/day  than  with  8  mg/day.  In  study
04,  the  most  common  TEAEs  were  dizziness  (38.1%  with
2  mg  versus  9.9%  with  placebo),  somnolence  (17.2%  versus
3.2%),  irritability  (14.2%  versus  5.0%),  headache  (13.4%
ersus  13.2%),  fall  (12.7%  versus  6.6%)  and  ataxia  (11.9%
ersus  0%).  Treatment  discontinuations  due  to  TEAEs  were
elatively  low  (placebo  5.8%,  8  mg/day  6.8%,  12  mg/day
7.9%)  (French  et  al.,  2012b).
In  study  305,  most  TEAEs  were  of  mild  or  moderate  sever-
ty,  and  severe  TEAEs  were  reported  in  only  6.6%,  9.3%  and
0.7%  of  patients  in  the  placebo,  perampanel  8  mg/day  and
2  mg/day  groups,  respectively  (French  et  al.,  2012b). The
EAEs  that  occurred  in  ≥10%  of  patients  in  any  treatment
roup  were  dizziness  (32.6%  and  47.9%  with  perampanel
 mg/day  and  12  mg/day  versus  7.4%  for  placebo),  somno-
ence  (12.4%  and  18.2%  versus  2.9%),  fatigue  (13.2%  and
6.5%  versus  8.1%),  and  headache  (8.5%  and  13.2%  versus
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13.2%  with  placebo)  (French  et  al.,  2012).  The  incidence  of
TEAEs  was  lower  during  the  maintenance  period:  dizziness
(5.1%  and  14.4%  versus  4.8%  with  placebo),  headache  (6.8%,
and  4.8%  versus  4.0%)  and  fatigue  (4.2%  and  6.7%  versus
2.4%)  (Ryvlin  et  al.,  2011). The  difference  in  TEAE  rates
between  the  titration  period  and  the  maintenance  period
might  be  explained  by  the  somewhat  rapid,  forced  titration
paradigm  of  2-mg  increments  each  week  over  the  6  weeks
of  titration.  Discontinuations  due  to  TEAEs  were  higher  in
perampanel-treated  patients  compared  with  placebo  (4.4%,
9.3%,  and  19%  with  placebo,  8  mg,  and  12  mg,  respectively)
(French  et  al.,  2012b). Rash  led  to  discontinuation  in  1.6%
perampanel  patients  versus  0%  in  placebo  patients.  No
abnormal  trends  in  laboratory  tests,  including  QTc,  were
observed  (French  et  al.,  2012b).
The  number  and  rates  of  rash  were  low  in  all  three  studies
without  evidence  of  a  dose  response  (Study  304:  placebo  =  3
(2.5%),  perampanel  =  5  (1.9%);  Study  305:  placebo  =  2  (1.5%),
perampanel  8  (3.2%);  Study  306:  placebo  =  2  (1.1%),  peram-
panel  9  (1.7%).  There  were  no  reports  of  Stevens-Johnson
syndrome.
Planned  studies
In  addition  to  the  open-label  extensions  of  the  perampanel
Phase  II  and  Phase  III  studies,  two  other  trials  are  underway.
The  ﬁrst  (NCT01393743)  will  explore  the  efﬁcacy  and
safety  of  adjunctive  perampanel  in  primary  generalized
tonic—clonic  seizures  and  aims  to  enroll  165  subjects.  The
second  (NCT01161524)  will  explore  the  effect  of  perampanel
on  cognition  and  growth  and  evaluate  its  safety,  tolerabil-
ity,  and  pharmacokinetics  in  adolescents  with  refractory
POS.
Tonabersat
Upsher  Smith  Laboratories,  Minneapolis,  Minnesota,  USA
H.  Steve  White,  PhD1 and  Paul  Durham,  PhD2
1Professor  and  Director,  Anticonvulsant  Drug  Develop-
ment  Program,  Department  of  Pharmacology  Toxicology,
University  of  Utah; 2Professor  and  Director,  Center  of
Biomedical  and  Life  Sciences,  Missouri  State  University
Introduction  and  rationale  for  developmentTonabersat  is  one  of  a  series  of  novel  benzoylamino  benzopy-
ran  compounds  initially  developed  by  SmithKline-Beecham
for  the  treatment  of  migraine  and  epilepsy.  The  tonaber-
sat  binding  site,  primarily  found  in  the  brain,  is  distinct
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rom  that  of  other  CNS  pharmacologic  agents,  including  anti-
igraine  compounds,  AEDs,  amino  acid  analogues,  and  ion
hannel  modulators.  Tonabersat  possesses  a  novel  mecha-
ism  of  action  related  to  stereospeciﬁc  activity  at  its  binding
ite,  which  may  be  related  to  uncoupling  of  neuronal  gap
unctions.  Further,  this  benzoylamino  benzopyran  class  of
ompounds  has  been  found  to  exhibit  anti-seizure  proper-
ies.  The  data  described  here  detail  the  current  studies
valuating  the  anti-seizure  proﬁle  of  tonabersat  and  its
echanism  of  action.
harmacology
n  both  mice  and  rats,  standard  in  vivo  and  in  vitro
odels  were  employed  to  establish  the  anti-seizure  pro-
le  of  tonabersat.  These  included,  but  were  not  limited
o,  models  of  generalized  tonic-clonic  seizures  (MES,
ocal  seizure  with  secondary  generalization  (6  Hz),  POS
ith  secondary  generalization  (hippocampal-kindled),  and
harmacoresistant  seizures  with  secondary  generalization
lamotrigine-resistant  kindled).  Toxicity  of  tonabersat  was
ssessed  with  the  minimal  motor  impairment  scale  (MMI)
r  rotarod  test,  and  minimal  behavioral  toxicity  was  sub-
equently  quantitated  (ED50 and  TD50)  at  the  time  of  peak
nticonvulsant  effect.  Additionally,  MES  data  were  used
o  correlate  tonabersat  plasma  exposure  with  anti-seizure
ctivity  and  model  a  relationship  between  efﬁcacy  and
onabersat  brain/plasma  concentrations.
The  mechanism  of  action  of  tonabersat  has  been  evalu-
ted  in  an  in  vivo  model  of  migraine.  Brieﬂy,  Sprague-Dawley
ats  were  injected  with  either  tumor  necrosis  factor-  (TNF-
),  capsaicin,  or  both  agents  (TNF- CAP)  to  stimulate
rigeminal  ganglion  neurons  to  induce  an  inﬂammatory  reac-
ion.  Cell-cell  communication  was  investigated  with  True
lue  dye-coupling  under  basal  and  inﬂammatory  conditions
n  the  presence  and  absence  of  tonabersat  (10  mg/kg  ip).
urther,  the  effects  of  inﬂammation  and  tonabersat  on  the
xpression  of  connexins  (Cx)  in  trigeminal  ganglion  neu-
ons  and  glia  were  evaluated  by  quantitative  RT-PCR  and
mmunohistochemistry  (Damodaram  et  al.,  2009) (Garrett
nd  Durham,  2008).
Across  a  number  of  preclinical  studies,  tonabersat
emonstrated  a  deﬁnitive  anti-seizure  proﬁle.  Tonabersat
emonstrated  a  dose-dependent  inhibition  of  electro-
raphic  bursting  in  the  in  vitro  K+ hippocampal  brain  slice
odel,  with  an  IC50 =  0.5  m.  While  tonabersat  was  unable
o  reduce  the  frequency  of  bursting  in  entorhinal  cor-
ex/hippocampal  brain  slices,  it  did  reduce  individual  burst
uration  by  ∼26%.  In  vivo,  tonabersat  demonstrated  low
oxicity  with  a  TD50 >  250  mg/kg  (mice)  and  >500  mg/kg
rats).  Tonabersat  signiﬁcantly  increased  the  threshold
or  electrically-induced  tonic  extension  seizures.  In  this
odel,  tonabersat  displayed  a  long  duration  of  action
e.g.,  up  to  12  h).  Further,  tonabersat  produced  both
ime-  and  dose-dependent  inhibition  of  tonic  extension
eizures  in  the  rat  MES  model,  which  speciﬁcally  cor-
elated  to  tonabersat  plasma  and  brain  concentrations.
hile  tonabersat  was  effective  against  audiogenic  seizures
PI  >  2000),  it  was  not  protective  against  6  Hz  (limbic)  or
lonic  seizures  induced  by  subcutaneous  administration  of
icrotoxin  or  bicuculline.  In  addition,  tonabersat  did  not
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nhibit  fully  expressed  seizures  in  either  hippocampal  or
amotrigine-resistant  kindled  rats.  While  tonabersat  exhib-
ted  anti-seizure  activity  similar  to  other  AEDs,  it  exhibited  a
igher  PI.
TNF- or  capsaicin  alone  did  not  increase  True  Blue
ye  movement.  In  contrast,  when  simultaneous  injec-
ion  of  TNF- and  capsaicin  did  increase  dye  movement
etween  neuronal  and  satellite  glial  cells  of  the  trigem-
nal  ganglion  (Damodaram  et  al.,  2009). This  ﬁnding
rovides  evidence  that  activation  of  trigeminal  ganglion
eurons  increase  cellular  communication  between  these
ell  types  via  gap  junctions.  RT-PCR  and  immunohisto-
hemistry  data  demonstrate  that  Cx26,  Cx36,  and  Cx40
re  expressed  in  the  trigeminal  ganglions  under  basal
onditions,(Damodaram  et  al.,  2009, Garrett  and  Durham,
008)  and  during  inﬂammatory  conditions  the  expression
f  these  connexins  is  up-regulated.  In  the  presence  of
onabersat,  the  inﬂammatory-induced  cellular  communi-
ation  between  the  neurons  and  satellite  glia  cells  was
bolished,  and  the  increase  in  Cx26  expression  was  inhibited
Damodaram  et  al.,  2009). Interestingly,  the  inhibitory
ffects  of  tonabersat  on  Cx26  expression  were  speciﬁc,
s  tonabersat  did  not  inhibit  the  up-regulation  of  Cx36  or
x40.
harmacokinetics  and  drug  interactions
nitial  studies  evaluating  the  clinical  pharmacokinetics  and
rug  interaction  potential  of  tonabersat  (2—80  mg)  in  both
ealthy  individuals  and  migraineurs  were  summarized  in  a
revious  Eilat  conference  report  (Bialer  et  al.,  2009).
lanned  studies
onabersat  is  currently  being  evaluated  in  Phase  I studies  as
n  investigational  drug  for  the  treatment  of  epilepsy.
alproic acid second generation derivatives
.  Bialer  and  B.  Yagen
Institute  for  Drug  Research,  School  of  Pharmacy,  Fac-
lty  of  Medicine,  The  Hebrew  University  of  Jerusalem,  Israel
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Valnoctamide (VCD)                              sec-Butyl -propylac etamide (SPD)
ntroduction
ince  Eilat  X  (2010),  signiﬁcant  progress  has  been  made
n  the  development  of  valnoctamide  (VCD)  as  well  as  sec-
utyl-propylacetamide  (SPD),  a  one-carbon  homologue  of
CD  (Bialer  and  White,  2010;  White  et  al.,  2012). VCD  is  a
NS-active  chiral  constitutional  isomer  of  valpromide,  the
o
(
t
SM.  Bialer  et  al.
orresponding  amide  of  valproic  acid  (VPA)  that  exhibits
tereoselective  pharmacokinetics  in  animals  and  humans
Bialer  and  Yagen,  2007;  Bialer,  2012). Both  VCD  and  SPD
ossess  two  chiral  centers  in  their  chemical  structure
denoted  above  with  the  asterisk  *).  VCD  (racemate)  was
ommercially  available  as  an  anxiolytic  drug  (Nirvanil®)  in
everal  European  countries  from  1964  until  as  recently  as
005  (Bialer  and  Yagen,  2007;  Bialer  and  White,  2010;  Bialer,
012),  and  it  is  now  being  developed  for  the  treatment  of
ipolar  disorder.  VCD  also  has  displayed  potential  in  epilepsy
nd  neuropathic  pain.
harmacology
nticonvulsant  activity  proﬁle  in  experimental  models
CD  (racemate  and/or  two  of  its  individual  enantiomers)
emonstrated  anticonvulsant  activity  in  a  wide  array  of
nticonvulsant  models  in  mice  (MES,  s.c.  pentylentetrazol
nd  6  Hz  psychomotor  seizures)  and  rats  (MES  and  s.c.
entylentetrazol)  as  described  in  the  previous  Eilat  X
onference  manuscript  (Bialer  et  al.,  2010).
As  summarized  in  Table  1,  SPD’s  anticonvulsant  activ-
ty  was  deﬁned  in  several  rodent  seizure  and  epilepsy
odels  including:  MES,  6  Hz  psychomotor,  s.c.  pentylen-
etrazol,  picrotoxin,  bicuculline,  audiogenic  and  corneal
nd  hippocampal  kindled  seizures  following  i.p.  adminis-
ration  (White  et  al.,  2012). SPD  was  also  evaluated  for  its
bility  to  block  benzodiazepine-resistant  status  epilepticus
nduced  by  pilocarpine  (rats)  and  soman  (rats  and  guinea
igs)  following  i.p.  administration.  SPD  was  tested  for  its
bility  to  block  excitotoxic  cell  death  induced  by  the  glu-
amate  agonists  N-methyl-D-Aspartate  (NMDA)  and  kainic
cid  (KA)  using  organotypic  hippocampal  slices  and  status
pilepticus-induced  hippocampal  cell  death  using  Fluoro-
ade  B  staining.  The  cognitive  function  of  SPD-treated  rats
hat  were  protected  against  pilocarpine-induced  convulsive
tatus  epilepticus  was  examined  10—14  days  post  SE  using
he  Morris  water  maze.
SPD  was  highly  effective  and  displayed  a  wide  PI  in
he  standardized  seizure  and  epilepsy  models  employed
Table  1).  SPD’s  wide  PI  values  demonstrate  that  it  is  effec-
ive  at  doses  well  below  those  that  produce  behavioral
mpairment.  Unlike  VCD,  SPD  also  displayed  anticonvul-
ant  activity  in  the  rat  lithium/pilocarpine  model  of  status
pilepticus.  Thirty  minutes  after  the  induction  of  status
pilepticus,  the  calculated  rat  ED50 for  SPD  against  convul-
ive  status  epilepticus  in  this  model  was  84  mg/kg.  SPD  was
ot  neuroprotective  in  the  in  vitro  organotypic  hippocam-
al  slice  preparation;  however,  it  did  display  hippocampal
europrotection  in  both  in  vivo  status  epilepticus  models
i.e.,  lithium/pilocarpine  and  soman)  and  treatment  after
he  onset  of  lithium/pilocarpine-induced  status  epilepticus
ith  SPD  resulted  in  cognitive  sparing  in  the  Morris  water
aze,  an  effect  that  was  associated  with  its  marked  anti-
eizure  effect  against  pilocarpine-induced  status  epilepticus
White  et  al.,  2012).
When  administered  20  and  40  min  after  status  epilepticus
nset,  SPD  (100—174  mg/kg)  produced  long-lasting  efﬁcacy
e.g.,  4—8  h)  against  soman-induced  convulsive  and  elec-
rographic  status  epilepticus  in  both  rats  and  guinea  pigs.
PD-ED50 values  in  guinea  pigs  were  67  mg/kg  and  92  mg/kg
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when  administered  at  the  onset  of,  or  40  min  after,  status
epilepticus  onset,  respectively.
Overall,  the  results  obtained  in  two  highly  treatment-
resistant  models  of  status  epilepticus  demonstrate  that  SPD
is  a  broad-spectrum  anti-seizure  compound  that  blocks  sta-
tus  epilepticus  induced  by  pilocarpine  and  soman  and  affords
in  vivo  neuroprotection  that  is  associated  with  cognitive
sparing.  SPD  activity  against  status  epilepticus  is  superior
to  diazepam  in  terms  of  rapid  onset,  potency  and  its  effect
on  animal  mortality  and  functional  improvement.
Other  pharmacological  properties:  Reversal  of  tactile
allodynia
The  antiallodynic  activity  of  VCD  and  two  of  its  individ-
ual  stereoisomers  (2R,3S)-VCD  and  (2S,3S)-VCD  in  the  spinal
nerve  ligation  (or  Chung)  model  for  neuropathic  pain  in
rats  was  described  in  the  Eilat  X  Conference  manuscript
(Bialer  et  al.,  2010). SPD’s  ED50 value  in  the  spinal  nerve
ligation  model  of  49  mg/kg  was  very  similar  to  that  of  VCD
(ED50 =  52  mg/kg)  (Kaufmann  et  al.,  2009,2010).
Teratogenicity
The  lack  of  notable  teratogenicity  of  VCD  and  (2R,3S)-VCD
and  (2S,3S)-VCD  in  SWV/Fnn  mice  which  are  highly  suscepti-
ble  to  VPA-induced  teratogenicity  was  previously  described
(Bialer  and  Yagen,  2007;  Bialer  et  al.,  2010). Following  a  suc-
cessful  Phase  IIa  study  in  patients  with  mania  funded  by  the
Stanley  Medical  Research  Institute  (SMRI)  (Bersudsky  et  al.,
2010),  the  SMRI  had  a  pre-IND  meeting  with  the  FDA-Division
of  Psychiatry  Products.  As  requested  by  the  FDA,  the  SMRI
in  collaboration  with  Yissum  (Hebrew  University  Technology
Transfer  Company  and  VCD  patents’  owner)  conducted  ter-
atogenicity  studies  comparing  VCD  to  VPA  (head-to-head)
in  mice,  rats  and  rabbits  at  Covance  Laboratories.  In  these
additional  studies,  VCD  in  contrast  to  VPA  failed  to  demon-
strate  teratogenic  potential  in  mice  and  rabbits.  In  rats
a  modest  teratogenic  signal  was  observed  at  plasma  con-
centrations  15-times  higher  than  VCD  therapeutic  plasma
levels.
A  follow-up  dose-response  study  with  high  doses  of  VCD
and  VPA  in  SWV/Fnn  mice  is  currently  in  progress  in  the  labo-
ratory  of  Prof.  Richard  H.  Finnell  at  the  University  of  Texas  in
Austin,  TX,  USA.  The  study  objective  is  to  perform  a  compar-
ative  evaluation  of  VCD  and  VPA.  Outcome  measures  of  this
study  include  assessment  of:  (a)  neural  tube  defect  response
rates,  and  (b)  soft  tissue  and  skeletal  integrity.  Embryos  will
also  be  collected  at  critical  times  during  development  for
genetic  microarray  studies  to  compare  the  impact  on  gene
expression  between  a  known  teratogen,  VPA,  with  VCD  to
see  how  they  impact  critical  genetic  pathways  that  regulate
normal  development.
Pharmacokinetics  in  experimental  animals
The  results  of  a  previously  conducted  stereoselective  phar-
macokinetic  analysis  of  VCD  were  summarized  in  the  Eilat  X
Conference  manuscript  (Bialer  et  al.,  2010).
SPD  pharmacokinetics  was  also  studied  following  i.p.
administration  60  mg/kg  to  naïve  male  Sprague-Dawley  rats.
SPD  was  found  to  have  a  clearance  of  0.3  L/h  that  was
o
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ainly  metabolic,  as  only  0.1%  of  the  SPD  dose  was  excreted
nchanged  in  the  urine.  In  rats,  SPD  displayed  a  7-fold  higher
learance  than  VCD  due  to  its  higher  lipophilicity.  SPD  vol-
me  of  distribution  was  3-times  greater  than  that  of  VCD
White  et  al.,  2012). As  a  consequence  of  these  opposite
rends  in  clearance  and  volume  of  distribution,  SPD  half-life
as  similar  to  that  of  VCD.
The  relationship  between  the  pharmacokinetic  proﬁle  of
PD  and  its  efﬁcacy  against  soman-induced  status  epilep-
icus  (PK-PD  relationship)  was  evaluated.  SPD  (60  mg/kg,
.p.)  was  administered  20  min  after  the  onset  of  status
pilepticus.  A  PK-PD  correlation  (assuming  linear  pharma-
okinetics)  showed  that  SPD  effective  plasma  levels  in  the
oman-induced  status  epilepticus  model  ranged  between
—40  mg/L  (20  min  post  seizure  onset)  and  12—50  mg/L
40  min  post  seizure  onset).  The  time  to  peak  effect
PD-tmax)  occurred  after  the  time  of  peak  plasma  levels
PK-tmax).  This  lag  time  may  indicate  a  slow  distribution
f  SPD  to  the  extra-plasmatic  active  site  responsible  for
PD’s  anticonvulsant  activity.  This  slower  distribution  to
he  active  site  may  contribute  to  the  fact  that  SPD’s
ffect  (responder  rate)  declined  at  a signiﬁcantly  slower
ate  than  SPD  plasma  levels  and  in  a few  rats  lasted  for
4  hours  when  SPD  was  administered  20  min  post  status
nset.
linical  data
ecently,  a  successful  double-blind  controlled  Phase  IIa
linical  trial  funded  by  the  SMRI  with  VCD  racemate  in
atients  with  mania  was  completed  (Bersudsky  et  al.,  2010;
ialer  et  al.,  2010). This  study  showed  that  VCD  could  be
n  important  substitute  to  VPA  in  women  of  child-bearing
ge  with  bipolar  disorder.It  is  worth  emphasizing  that  based
n  head-to-head  comparison  with  VPA  in  mice,  rats  and
abbits  (unpublished  data  on  ﬁle)  VCD  is  the  ﬁrst  potential
ffective  mood  stabilizer  without  signiﬁcant  teratogenicity
n  animal  models.
ngoing  and  planned  studies
lthough  VPA  is  the  most  prescribed  AED,  its  clinical  use
s  restricted  in  women  of  child-bearing  age  and  in  children
ue  to  its  teratogenicity  and  hepatotoxicity,  respectively
Bialer  and  Yagen,  2007). The  development  of  VCD  and  its
ntroduction  as  a  new  and  potentially  non-teratogenic/non-
epatotoxic  CNS  agent  that  is  more  potent  than  VPA,  may
ffer  a  safer  alternative  for  the  treatment  of  patients  with
ipolar  disorder,  epilepsy  and  neuropathic  pain  (Bialer  and
hite,  2010). Following  the  successful  Phase  IIa  clinical
rial,  VCD  is  currently  undergoing  a  3-week  SMRI-funded
hase  IIb,  randomized  double-blind  multicenter  study  in  300
atients  with  bipolar  manic  episodes.  The  study  is  a  3-arm
onotherapy  parallel  group  trial  in  which  patients  are  ran-
omized  to  placebo  (n  =  120),  VCD  1500  mg/day  (n  =  120)
nd  risperidone,  up  to  6  mg/day  (n  =  60).  The  study’s  major
bjective  is  to  evaluate  the  efﬁcacy  of  VCD  compared  to
lacebo  in  patients  with  acute  manic  or  mixed  episodes.
isperidone  is  included  as  an  active  control  to  ascertain  the
rial’s  assay  validity.
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X-765
rench  J1,  Martin  M2,  Paskavitz  J2,  Wright  C2.
1MDNYU  Comprehensive  Epilepsy  Center,  New  York,  NY,
SA; 2Vertex  Pharmaceuticals  Incorporated,  Cambridge,  MA,
SA.
ntroduction  and  rationale  for  development
lthough  many  treatments  are  available  in  the  United
tates,  there  are  approximately  800,000  patients  with
pilepsy  that  continue  to  have  seizures  despite  treatment
ith  2  or  more  antiepileptic  drugs  (AEDs).  Thus,  there  may
e  important  components  underlying  the  disease  that  are
ot  being  addressed  by  current  therapies.  There  is  increas-
ng  evidence  that  inﬂammation  plays  an  important  role  in
stablishing  and  maintaining  seizures  (Perucca  et  al.,  2007).
urgical  specimens  obtained  from  human  brains  of  patients
ith  treatment-resistant  epilepsy  show  a  number  of  inﬂam-
atory  features,  including  elevated  levels  of  interleukin
onverting  enzyme  (ICE,  also  known  as  caspase-1)  and  inter-
eukin  1  (IL-1) and  an  increase  in  IL-1 receptors  (Ravizza
t  al.,  2008;  Vezzani  et  al.,  2008). These  human  brain  studies
uggest  that  ICE/IL-1  may  be  involved  in  causing  epilepsy,
articularly  epilepsy  that  is  resistant  to  current  treatments.
everal  nonclinical  experiments  support  an  important  role
or  ICE/IL-1  systems  in  epilepsy  and  indicate  that  inhibition
f  ICE/IL-1  has  therapeutic  potential  for  treating  epilepsy
Vezzani  et  al.,  2008).
harmacology
X-765  (developed  by  Vertex  Pharmaceuticals  Incorporated)
s  a  selective  and  reversible  inhibitor  of  interleukin-
onverting  enzyme  (ICE;  srtucture  above)  (Wannamaker
t  al.,  2007). VX-765  is  currently  in  Phase  2  development.
hase  IIa  study
 6  week  phase  IIa  randomized,  double-blind,  multicen-
er,  placebo-controlled  study  was  completed  in  subjects
18—64  years  old)  with  treatment-resistant  partial  epilepsy
eceiving  1—4  concomitant  AEDs.  Treatment  resistance  was
eﬁned  as  failure  to  achieve  seizure  control  despite  ade-
uate  trials  of  2  different  AEDs.  Subjects  were  randomized
:1  to  VX-765  900  mg  tid,  (n  =  48)  or  placebo  (n  =  12).
(
o
e
tM.  Bialer  et  al.
ubjects  had  to  have  at  least  6  observable  partial  onset
eizures  (POS)  during  the  6  weeks  between  screening  and  the
tart  of  the  treatment  period  (the  ‘‘baseline  period’’),  and
t  least  one  seizure  in  3  of  the  6  weeks.  The  6-week  treat-
ent  period  was  followed  by  a 6-week  observation  period
ff  study  drug.  The  primary  endpoint  was  safety  and  toler-
bility.  Secondary  endpoints  included  percent  reduction  in
eizure  frequency  during  the  6  week  treatment  period  rela-
ive  to  the  baseline  period,  percent  of  subjects  with  ≥50%
eduction  in  seizure  frequency  (‘‘responder-rate’’)  during
he  6  week  treatment  period  relative  to  the  baseline  period,
nd  percent  of  subjects  that  become  seizure-free  during  the
ast  2  weeks  of  the  treatment  period.
afety  and  tolerability
 total  of  35  subjects  (72.9%)  in  the  VX-765  group  had  at
east  1  TEAE  during  the  6  week  treatment  period  compared
ith  10  subjects  (83.3%)  in  the  placebo  group.  The  most
ommon  TEAE  was  dizziness  (16.7%).  One  subject  in  the
X-765  group  had  a  rash  that  led  to  early  discontinuation
rom  treatment.  Serious  TEAE  occurred  in  6.3%  (3/48)  of
X-765  subjects  (hernia  surgery,  pain,  and  acute  worsening
f  complex  partial  seizures  post-treatment)  and  0%  (0/12)  of
lacebo  subjects.  All  three  serious  TEAEs  were  determined
y  the  need  for  hospitalization.
fﬁcacy  results
 summary  of  the  secondary  efﬁcacy  assessments  are  shown
n  Table  4.  The  mean  percent  reduction  in  seizure  rates
ere  15.6%  in  the  VX-765  group  and  7.0%  in  the  placebo
roup.  There  was  a ≥50%  reduction  in  seizures  in  18.8%  of
ubjects  in  the  VX-765  group  versus  8.3%  in  the  placebo
roup.  The  differences  in  reduction  in  seizure  rate  and
0%  responder  rates  did  not  meet  statistical  signiﬁcance
etween  the  two  groups.  Overall,  12.5%  of  the  VX-765
ubjects  were  seizure  free  during  the  last  2  weeks  of  treat-
ent  versus  0%  in  the  placebo  group.
Because  animal  data  suggested  a  possible  delayed  effect
f  VX-765,  a  post  hoc  analysis  was  performed  to  deter-
ine  whether  stronger  effects  might  be  seen  later  in  the
reatment  period.  We  evaluated  a  4-week  ‘‘hybrid’’  period
onsisting  of  the  ﬁnal  2  weeks  of  treatment  plus  the  2  week
ost-treatment  (follow-up)  period  (Tables  5  and  6).  During
he  hybrid  period,  there  appeared  to  be  a  trend  towards  a
etter  50%  responder  rate  in  the  VX-765  subjects  (31.3%  in
he  VX-765  group  compared  with  8.3%  in  the  placebo  group).
hese  post  hoc  analyses  suggest  that  there  may  be  a  delayed
eneﬁcial  effect  of  VX-765  that  persists  for  some  time  after
rug  is  discontinued.  Future  studies  can  further  evaluate
hese  early  observations.
ngoing  clinical  studies
 double-blind,  placebo-controlled,  multicenter,  interna-
ional  study  in  treatment  resistant  POS  has  been  initiated
VX-765-402).  This  study  is  a  13-week  dose-ranging  study
f  VX-765,  as  adjunctive  treatment,  to  evaluate  the
fﬁcacy  and  safety  in  subjects  with  treatment-resistant  par-
ial  onset  seizures.  However,  on  September  25,  2012,  Vertex
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Table  4  Summary  of  VX-765  efﬁcacy  results.
Endpoint,  (%)  (95%  Cl)  Placebo  N  =  12  VX-765  N  =  48  Treatment  difference
(VX-765  minus  placebo)
%  Reduction  in  seizure  rate  (mean)  7.0  (−22.3,  36.4)  15.6  (1.0,  30.2)  8.6  (−24.3,  41.5)
50% responder  rate  in  treatment  periord  8.3  (0.2,  38.5)  18.8  (8.9,  32.6)  10.5  (−18.9,  26.6)
% Seizure-free  during  last  2  weeks  of  treatment
period
0  (0,  26.5)  12.5  (4.7,  25.2)  12.5  (−135,  25.0)
Table  5  Post  hoc  analyses  of  VX-765  efﬁcacy  results.
Endpoint,  (%)  (95%  Cl)  Placebo  N  =  12  VX-765  N  =  48  Treatment  difference
(VX-765  minus  placebo)
%  Reduction  in  seizure  rate  (mean)  in  hybrid
perioda
8.9  (−14.4,32.1)  29.4  (17.8,  41.0)  20.5  (−5.5,  46.6)
50% Responder  rate  in  hybrid  perioda 8.3  (0.2,  38.5) 31.3  (18.7,  46.3) 23.0  (−8.4,  40.2)
% Seizure-free  during  last  2  weeks  of  follow-up
period
0  (0,  26.5) 18.8  (8.9,  32.6) 18.8  (−8.5,  32.0)
% Seizure-free  in  hybrid  perioda 0  (0,  26.5)  6.3  (1.3,  17.2)  6.3  (−19.1,  17.2)
a Hybrid = last 2 weeks of treatment plus ﬁrst 2 weeks of follow up. The hybrid period was 4 weeks relative to the 6 weeks of the
baseline period.
Table  6  Comparison  of  VX-765  initial  results  with  ‘‘delayed  effect’’  model  (post  hoc  analysis).
Endpoint,  (%)  (95%  Cl)  Treatment  period
Treatment  difference  (VX-765
minus  placebo)
Hibrid  period
Treatment  difference  (VX-765
minus  placebo)
%  Reduction  in  seizure  rate  (mean)  [during
treatment  period  vs.  hybrid  period]
8.6  (−24.3,  41.5)  20.5  (−5.5,  46.6)
50% Responder  rate  [during  treatment  period
vs. hybrid  period]
10.5  (−18.9,  26.6)  23.0  (−8.4,  40.2)
% Seizure-free  [during  last  2  weeks  of
follow-up  period]
12.5  (−13.5,  25.0)  18.8  (−8.5,  32.0)
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2.1  (−24.
made  a  business-related  decision  to  stop  enrollment  in  this
study.  Approximately  40  subjects  were  advancing  through
the  8-week  baseline  period  and  almost  20  subjects  had  been
randomized  into  the  treatment  phase  of  the  study.
Subjects  will  be  permitted  to  stay  in  the  study  for  its
full  planned  duration.  Though  substantially  underpowered
for  rigorous  statistical  analyses;  data  will  be  analyzed  and
thoroughly  examined  for  safety  assessments  and  potential
effectiveness  of  treatment.
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ntroduction
KP3089  is  a  novel  tetrazole  derived  compound  with  one
hiral  center  (denoted  above  with  an  asterisk).  It  is  active
n  a  broad  range  of  animal  models  of  epilepsy.  It  is  currently
n  Phase  II  clinical  development  at  SK  Life  Science.
harmacology
nticonvulsant  proﬁle  in  experimental  models
KP3089  displays  a  broad-spectrum  of  anticonvulsant  activ-
ty  in  rodent  seizure  and  epilepsy  models  (Tables  1  and  2).
t  has  been  previously  reported  to  prevent  minimal
lectroshock-induced  seizures  in  both  mice  and  rats,
ith  ED50 values  of  9.8  mg/kg,  i.p.  and  1.9  mg/kg,
.o.,  respectively.  In  mice,  YKP-3089  prevents  minimal
lonic  seizures  induced  by  subcutaneously  administered
entylentetrazol  and  picrotoxin  with  ED50’s  of  28.5
nd  34.5  mg/kg,  i.p.,  respectively.  YKP3089  was  also
ffective  against  pentylentetrazol-induced  clonic  seizures
nd  lithium/pilocarpine-induced  status  epilepticus  in  rats
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ollowing  i.p.  administration  (ED50:  14  and  7  mg/kg,  i.p.,
espectively).  YKP3089  was  found  to  be  effective  in
wo  models  of  POS,  i.e.,  the  hippocampal  kindled  rat
ED50 =  16.4  mg/kg,  i.p.)  and  the  mouse  6  Hz  psychomotor
eizure  model  (Tables  1  and  2).  It  is  worth  noting  that  lit-
le  change  in  the  potency  of  YKP3089  was  observed  in  the
 Hz  test  when  the  current  was  increased  from  22  to  32,  to
4  mA,  with  ED50s  of  11,  18  and  17  mg/kg,  i.p.  respectively.
ther  pharmacological  properties
s  described  previously,  YKP3089  shows  activity  in  mouse
nd  rat  models  of  anxiety  and  is  more  efﬁcacious  than
abapentin  in  the  spinal  nerve  ligation  (Bennett  and  Chung)
odel  of  neuropathic  pain  (Bialer  et  al.,  2010). YKP3089
isplays  neuroprotective  activity  in  the  hypoxia-induced
ethality  mouse  model.
oxicology
KP3089  was  negative  in  all  genotoxicity  assays  tested  (Ames
acterial  reverse  mutation,  mouse  lymphoma  and  in  vivo  rat
one  marrow  micronucleus  studies).  No  evidence  of  terato-
enicity  was  observed  in  reproductive  studies  in  rats  and
abbits.  YKP3089  did  not  affect  cardiovascular  functions  in
 telemetry  cardiovascular  study  in  monkeys.
linical  pharmacokinetics
ollowing  single  oral  administration,  plasma  YKP3089  lev-
ls  were  dose-proportional.  In  single  dose  studies,  YKP3089
harmacokinetic  parameters  were  linear  over  a  large  dose
ange  (5—750  mg),  with  a  median  time  of  peak  concentra-
ion  of  1.5—3.5  hours,  a  mean  volume  of  distribution  (Vd/F)
f  37—55  L,  a  half-life  of  30—75  h  and  a  mean  oral  clear-
nce  (CL/F)  of  0.63  L/h.  In  a  multiple-dose  14-day  study  with
nce-daily  dosing,  both  Cmax and  AUC  correlated  linearly
ith  the  dose  over  the  range  of  50  mg/day  to  300  mg/day.
here  was  no  signiﬁcant  effect  of  food  (high-fat  diet)  on
KP3089  pharmacokinetics.
olerability  and  adverse  events  proﬁle
n  Phase  I  healthy  volunteer  studies,  YKP3089  was  well-
olerated  after  single  oral  doses  ranging  from  5  mg  to
50  mg  In  multiple  ascending  oral  dose  studies  in  healthy
olunteers  of  14—17  days  duration,  doses  ranging  from
0  mg/day  to  200  mg/day  were  well  tolerated.  Doses
f  250—300  mg/day  were  associated  with  a  higher  inci-
ence  of  CNS-related  TEAEs.They  were  mild  to  moderate
n  intensity  and  resolved  rapidly.  No  clinically  signif-
cant  changes  in  ECGs  or  laboratory  parameters  were
bserved.
ngoing  Phase  II  study Phase  II,  multicenter,  double-blind,  randomized,  placebo
ontrolled  trial  to  evaluate  the  efﬁcacy  and  safety  of
djunctive  YKP3089  in  subjects  with  treatment-resistant
OS  (NCT01397968)  is  ongoing.
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